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ELECTROCONVULSIVE THERAPY
This motor won’t start
My mate takes me to the hospital, again
Why? Drugs don’t work.
My mouth is a dry, bowel clogged,
brain slow, singed heart falters.
Life is shot.
I wish I could fade into a junkyard,
with other carcasses of colonels and cars.
Electricity, doctors insist.
They want to jumpstart me.
They should give up, hang up their 
cables, like the noose I dream of.
How can a seizure help?
Again wife and daughters plead.
We are destined to failure;
I finally yield.
They wheel me down,
put a mask on my face,
drugs in weakened veins.
I smell apples.
Four more times:
dreams of stockcars and winning,
and, they say, convulsions.
The scent of fruit and
the buzz of honeybees return to me.
My brain begins to rev,
the starter motor works;
we used to neck in my t-bird.
I feel my sex jumping.
My angels surprises me
in the golden courtyard
as I argue merits of politics, ECT,
and John Deere tractors.
She wonders at my smile.
Why shouldn’t I? It is harvest time,
and I love to reap god’s bounty.
I always wanted a flaming red sportscar.
Together we stroll, discuss prices, 
engines,
and admire the orange mums.
Elspeth Cameron Ritchie, M.D, 1993
printed with permission of dr. Elspeth 
Cameron Ritchie.
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Chapter 1
General introduction





Major depressive disorder (MDD) is one of the oldest well-recognized medical disorders 
(1). MDD is a seriously health problem with a high impact on disability and morbidity. 
Its lifetime prevalence is 16-20% worldwide and it has been projected to become 
the second most common cause of disability by 2020 (2, 3). MDD is characterized 
by a depressed mood and/or markedly diminished interest or pleasure in almost all 
activities for at least two weeks. Further, patients have other symptoms like:
- significant weight loss, weight gain or decrease or increase in appetite
- insomnia or hypersomnia
- psychomotor agitation or retardation
- fatigue or loss of energy
- feelings of worthlessness or excessive or inappropriate guilt
- diminished ability to think or concentrate, or indecisiveness
- recurrent thoughts of death or suicide or suicide plans
In total, patients must have five or more of the above described symptoms according 
to the standard classification of mental disorders (DSM-5) to meet the criteria for MDD.
The DSM-5 assumes that MDD is a single category and that clinical presentations 
only vary in severity (4). This results in MDD being a heterogeneous disorder with no 
established etiology and an inconsistent response to treatment (5). Therefore, in this 
thesis we focused on patients with severe MDD, especially those with melancholic 
and/or psychotic features. In melancholic depression, episodes are characterized 
by psychomotor retardation or agitation, weight loss, inappropriate guilt, lack of 
reactivity and/or diurnal variation of mood (6). A depression with psychotic features 
is a severe form of MDD. Psychotic features are generally with mood congruent 
delusions, such as delusions of guilt, nihilism and poverty and infrequently with 
(acoustic) hallucinations. These subtypes of depression have a low placebo response 
(7). Their response to biological treatments such as antidepressants and ECT is 
superior to response to psychotherapy (8).”
Electroconvulsive therapy in major depression
Electroconvulsive therapy (ECT) is the oldest somatic treatment in psychiatry still in 
use. It was introduced in 1938 by the Italian clinicians Ugo Cerletti and Lucio Bini and 
soon after ECT spread quickly in popularity. It started as a treatment for schizophrenia, 
but greater effectiveness for depression was shown soon after its discovery (9). The 
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success of ECT was clear, especially after advances in anesthesia techniques in the 
1950s allowed for the use of general anesthesia and muscle relaxation (10). It was the 
most effective treatment for MDD before the introduction of antidepressants (11) with 
an 80-90% response rate in early studies. After the introduction of antidepressants in 
the 1960’s and especially because of the ‘antipsychiatry movement’ in the 1970s and 
1980s there was a substantial decline of ECT use at least in the Netherlands.
From the 1990’s the use of ECT revived again. However, the widespread use of 
antidepressants changed the patient population that currently receives ECT. In the 
1940s it was a first line treatment of depression and from the 1990s until now it is 
mainly used for patients who are resistant to all pharmacologic treatments.
ECT involves deliberately inducing generalized seizures by administering an electrical 
stimulus of 0.8 to 0.9 Ampere for several seconds to a patient’s brain via electrodes 
applied to scalp (12). Today, brief pulse wave ECT rather than sine-wave ECT with a 
constant voltage and energy is recommended (13). A generalized seizure is necessary 
for ECT to be effective. Seizure threshold is the minimum stimulus dose at which a 
generalized seizure is elicited, therefore it is necessary to exceed the seizure threshold.
In the Netherlands, ECT is usually administered twice weekly under general 
anesthesia. Anesthesia is achieved after premedication with glycopyrrolate, with 
propofol (an anaestheticum), alfentanil (an analgesic) and succinylcholine (a muscle 
relaxant). Physiological monitoring includes pulse oximetry, non-invasive blood 
pressure, electrocardiogram and electroencephalogram. ECT is considered as a safe 
treatment with few side effects: post-ECT confusion, headache and some patients 
suffer from anterograde and/or retrograde amnesia after ECT (14). However, amnesia 
is mostly temporary and related to the period of impairment immediately following 
ECT (15).
Several hypothesis have been studied, but underlying cerebral mechanisms of ECT 
still remain unclear (16).
A meta-analysis carried out in 2003 (17) found that ECT was significantly more 
effective when compared to sham (simulated) ECT in adult patients with depressive 
disorder with a mean difference in decrease of HAM-D score of 9.7 points in favor 
of real ECT. Furthermore, they found ECT to be significantly more effective than 
pharmacotherapy. This meta-analysis also found bilateral ECT to be more effective 
than unilateral ECT. Altogether, ECT is a highly effective treatment for patients with 
1
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severe depression, especially those with psychotic features (18). Regardless of the 
substantial proof of efficacy, ECT still continues to be one of the most controversial, 
stigmatized and misunderstood treatments in medicine.
Predictors of ECT efficacy in severely depressed patients
Despite the high response rates of ECT in severe depression, up to 30-45% of the 
patients do not achieve full remission (19). Only few clinical predictors of efficacy of 
ECT in major depression are known: previous successful ECT treatment (20), shorter 
duration of the index episode (21, 22) and the presence of delusions (23-25). Therefore, 
reliable predictors of ECT efficacy would be useful for patient selection.
Medication resistance as a predictor for ECT efficacy
In the Netherlands, ECT is mainly used for patients who do not respond to adequate 
trials of antidepressants (medication resistance) (26). A substantial number of patients 
suffering from severe depressive disorder fail to respond to adequately performed 
treatment with antidepressants.
The literature seems to be divided as to whether medication resistance has a negative 
influence on efficacy of ECT.
Recent (American) studies found that depressed patients who did not respond 
to adequate treatment with antidepressants had lower remission rates to ECT 
compared to patients who did not receive adequate treatment with antidepressants 
(27-30). Other (predominantly European) studies found no difference (31-34) in 
efficacy between patients who did or did not receive adequate treatment with 
antidepressants.
If antidepressant refractory patients show a decreased efficacy of ECT it should be 
considered earlier in the treatment algorithm in severely depressed patients instead 
of being a ‘last resort’ treatment.
Polarity as a predictor of ECT efficacy
ECT is widely used for the treatment of severe and treatment resistant unipolar and 
bipolar depression. However, it remains unclear whether differences in ECT efficacy 
between unipolar and bipolar depression are present. This is mostly due to the fact 
that the efficacy of ECT (and antidepressants) in bipolar depression is not well studied, 
since bipolarity often is an exclusion criterion in randomized clinical trials (35). This 
is unfortunate, since bipolar disorder is mainly a ‘depressive’ disorder with limited 
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treatment options, and there is a risk for a switch to hypomania or mania caused by 
treatment with antidepressants (36). Also, the efficacy of antidepressant treatment 
in bipolar depression is questionable (37). Therefore, assessing the efficacy of ECT in 
bipolar depression is clinically relevant.
Older age as a predictor of ECT efficacy
The literature on whether elderly depressed patients show higher ECT efficacy 
compared to younger depressed patients is inconclusive. Higher efficacy of ECT in 
older patients with major depression was found in several studies (38-40), but not in 
all (41-43). However, in two of the latter three studies the population was a mixture 
of patients with major depression, schizophrenia and schizoaffective disorder (42, 
43). Two meta-analyses found an association between older age and higher efficacy 
of ECT (18, 21). Nonetheless, this association was weak and heterogeneity between 
studies was substantial.
ECT often is the treatment of choice in elderly severely depressed patients due to poor 
tolerance of psychotropic medication and comorbid medical illness. Therefore, it is 
important to investigate whether older age is a predictor of higher efficacy of ECT.
Psychomotor disturbance and psychotic features as predictors of ECT efficacy
Psychomotor disturbance, especially psychomotor retardation, is a central feature 
of severe major depression and includes motor and cognitive impairments affecting 
motility, speech and ideation (44). Psychomotor retardation is one of the strongest 
indicators of melancholic depression (45). Melancholic features are associated 
with biological dysregulation, like shorter REM latency and dexamethasone non 
suppression (46). Therefore, it is possible that psychomotor disturbance is a predictor 
for higher efficacy of ECT, since ECT is a biological treatment, which may correct such 
dysregulation. Hickie et al. (1996)(47) found marked psychomotor disturbance to be 
associated with superior response to ECT in depressed patients.
Further, as mentioned, the presence of psychotic features in depression is a convincing 
predictor for ECT efficacy.
Since psychomotor retardation and psychotic features might be more common in 
elderly patients (38, 48), it is possible that psychomotor disturbance and psychotic 
features partly explain the finding that older age predicts higher ECT efficacy.
1
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Predictors for early relapse after successful ECT
High rates of relapse after successful ECT treatment remain a major problem (49). A 
recent meta-analysis found a relapse rate of 51% in the first 12 months following ECT, 
with the majority of patients (38%) relapsing within the first 6 months (50). Therefore, 
in order to prevent relapse, identifying predictors of relapse after ECT may be useful.
Only few clinical predictors of post-ECT relapse are known. The risk of relapse appears 
to be reduced by continuation treatment with a tricyclic antidepressant (TCA), the 
combination of a TCA and lithium or continuation ECT (51). Moreover, medication 
resistant patients may be prone to early relapse after successful ECT (30, 52). Little 
is known about possible biological predictors for relapse after successful ECT and 
other potential clinical predictors.
HPA axis hyperactivity as predictor of relapse after successful ECT
Major depression is associated with both hypocortisolemia and hypercortisolemia, 
with hypocortisolemia being more prevalent in patients with chronic major 
depression (53). MDD occurs frequently in patients with endocrine disorders affecting 
the hypothalamic-pituitary-adrenal (HPA) axis, such as Cushing disease and Addison 
disease, a primary adrenocortical insufficiency which leads to glucocorticoid- and/
or mineralocorticoid deficiency (54). Studies have reported hyperactivity of the HPA 
axis in MDD leading to elevated cortisol levels and less suppression of cortisol on the 
dexamethasone suppression test (DST) (55-57). Furthermore, it is reported that an 
imbalance of mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) may 
contribute to HPA axis hyperactivity (58).
A meta-analysis found that post treatment persistent non-suppression on the DST 
after clinical treatment response (ECT and/or antidepressants) in MDD was strongly 
associated with poor long-term outcome (59). When focusing on ECT treatment alone, 
inconclusive results have been reported. Several studies found no association (60-62). 
One study found a poorer outcome in patients with persistent non-suppression on the 
DST (63) whereas another study found better outcome in persistent non-suppressors 
after successful ECT (64).
Therefore, it is important to investigate whether persistent HPA axis hyperactivity 
after successful ECT predicts early relapse. If such a relation would exist it might be 
useful to continue ECT treatment in clinically improved patients with persistent HPA-
axis hyperactivity until normalization of the HPA axis is attained.
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Aims of this thesis
Only few convincing predictors of ECT efficacy in MDD and even fewer predictors of 
relapse after successful ECT are known. Further, high relapse rates after successful 
ECT remain a major cause for concern. For these reasons, it is of value to investigate 
potential predictors for ECT efficacy and for relapse after successful ECT.
The aims of this thesis are:
A. To assess the possible influence of medication resistance on the efficacy of 
subsequent ECT (chapter 2, 3)
B. To compare the efficacy of ECT in bipolar depression to the efficacy of ECT in 
unipolar depression (chapter 4)
C. To test the hypothesis that older age predicts higher ECT efficacy in MDD (chapter 
5)
D. To explore the hypothesis that persistent HPA axis hyperactivity after successful 
bilateral ECT course, predicts early relapse of MDD (chapter 7)
1
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Objective: To examine the predictive value of resistance to a tricyclic antidepressant 
(TCA) and lithium with respect to the efficacy of subsequent electroconvulsive 
therapy (ECT).
Method: This open prospective study was conducted in the inpatient depression 
unit of a university hospital in The Netherlands. Patients were enrolled in the study 
from October 1996 to June 2002 and had to meet DSM-IV criteria for major depressive 
disorder. Eighty-six patients were treated twice weekly with ECT until recovery or no 
progress during at least 10 bilateral treatments. Patients were maintained drug free 
during the ECT treatment. Clinical evaluation of depressive symptoms was performed 
each week; scores on the 17-item version of the Hamilton Rating Scale for Depression 
(HAM-D) were obtained 1 to 3 days prior to ECT and 1 to 3 days after treatment 
termination. The primary outcome criterion was defined as the mean difference in 
HAM-D score before and after ECT for patients who had received adequate treatment 
with a TCA and lithium compared with patients who had not received adequate 
treatment with a TCA and lithium. Adequate treatment was defined as 4 weeks 
taking a predefined plasma level of a TCA; nonresponders had lithium added to the 
medication, and the minimal duration of the lithium addition was 3 weeks with a 
plasma level of at least 0.6 mmol/L. Independent samples t test was used to analyze 
this primary outcome criterion.
Results: According to the primary outcome criterion, patients who had received 
adequate treatment with a TCA and lithium (N = 56) had a mean difference in HAM-D 
score pre-ECT and post-ECT of 16.4 compared to a HAM-D score difference of 19.5 in 
the patient group who had received inadequate treatment with a TCA and lithium 
(N = 30). This inequality in differences in mean HAM-D scores is not significant (p = .2).
Conclusion: In the present study sample, treatment failure with adequate 
pharmacotherapy with a TCA and lithium addition appears to be unrelated to 
outcome following subsequent ECT.
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INTRODUCTION
Electroconvulsive therapy (ECT) was recognized as the most effective treatment 
for major depression before the introduction of antidepressants (1). Early studies 
reported that 80% to 90% of depressed patients showed substantial clinical response 
to ECT (2). The widespread use of antidepressant pharmacotherapy as a treatment 
for depression has changed the population that currently receives ECT. In The 
Netherlands, ECT is mainly used for patients who do not respond to adequate trials 
of antidepressants, including selective serotonin reuptake inhibitors (SSRIs), tricyclic 
antidepressants (TCAs), TCAs with lithium addition, and monoamine oxidase inhibitors 
(3). Thus, failure to respond to antidepressants is the most common indication for 
ECT. Despite this change in the indication for ECT, there is little consensus about the 
impact of medication treatment failure on the efficacy of subsequent ECT.
Several uncontrolled studies have suggested that clinical outcome of ECT is 
independent of previous failure to respond to antidepressant pharmacotherapy (4-7). 
These studies were uncontrolled, because response to ECT was only examined among 
patients who were thought to be medication treatment failures. A comparison patient 
sample that had not received adequate antidepressant pharmacotherapy prior to ECT 
was not included. Other methodological concerns included weak or inappropriate 
criteria for medication resistance and nonuniform outcome criteria.
Two studies used a prospective design to investigate this subject (8,9). The first 
study examined a sample of 53 depressed patients (8). Only patients randomly 
assigned to bilateral ECT were included. Patients who failed to respond to adequate 
antidepressant pharmacotherapy had lower response rates to ECT (50%) than 
patients who had received inadequate antidepressant pharmacotherapy (86%) (8).
The second study examined a sample of 100 nonpsychotic depressed patients (9). 
The patients in this study were treated predominantly with low-dose right unilateral 
ECT. This form of ECT is considered to be inadequate. Patients who failed to respond 
to adequate antidepressant therapy again had lower response rates to ECT (63%) 
compared to patients who had received inadequate antidepressant pharmacotherapy 
(91%) (9).
The influence of medication resistance on response to ECT has been investigated 
in The Netherlands in 2 studies (10,11); neither of these studies found an influence 
of medication treatment failure on the outcome of subsequent ECT. The first study 
examined 41 depressed inpatients (10). No significant difference in response rate 
2
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was found in patients who had received adequate antidepressant treatment prior 
to ECT (72%) compared to patients who had received inadequate antidepressant 
pharmacotherapy (67%) (10).
The second study examined 104 patients who met DSM-IV criteria for major depressive 
disorder (11). Again, no significant difference in response rate was found between 
patients who received adequate antidepressant treatment prior to ECT (62.5%) and 
patients who received inadequate antidepressant treatment (81.1%) (11).
In the United Kingdom, medication-refractory and medication-nonrefractory patients 
are also reported to have the same antidepressant response with ECT (12). Apart from 
European studies casting doubt on the influence of antidepressant treatment failure 
on ECT response, a recent study from the United States found that treatment failure 
with antidepressant medication as assessed by the Antidepressant Treatment History 
Form (ATHF) was not predictive of remission status after ECT (13). The ATHF has been 
the reference in the reported instances of treatment resistance. Thus, the results of 
the above-mentioned studies regarding the influence of medication treatment failure 
are somewhat conflicting.
Newer antidepressants have more tolerability and safety benefits than older TCAs. 
Similar efficacy in unselected depressed samples is suggested by some authors (14). 
However, the TCAs demonstrated greater efficacy in severely depressed patients and 
in depressed inpatients. Other studies have shown TCAs to be more efficacious than 
SSRIs and other newer antidepressants in depressed inpatients (15-18).
A substantial number of patients suffering from depressive disorder fail to respond to 
adequately performed treatment with antidepressants. Several treatment strategies 
have been proposed to treat such refractory depression, of which the best studied 
is lithium addition (19); this latter meta-analysis is quite convincing and confirms 
the efficacy of this strategy. Two other studies have confirmed the efficacy of the 
treatment strategy of a TCA followed by lithium addition (20,21).
It is possible that resistance to a “stronger” antidepressant trial (i.e., adequate 
treatment with a TCA and lithium) results in a significantly poorer response to ECT. 
No study has examined the predictive value of treatment failure of a TCA and lithium 
with respect to the efficacy of ECT; the present study attempts to address this issue.
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METHOD
This open prospective study was carried out in the inpatient depression unit of 
the Department of Psychiatry at the University Hospital-Erasmus Medical Center, 
Rotterdam, The Netherlands. Patients were enrolled in the study from October 1996 
to June 2002. Informed consent was obtained, and written informed consent was 
also required.
Patients had to meet the DSM-IV criteria for major depressive disorder to be enrolled 
in the study. Patients with organic brain syndrome, schizophrenia, or bipolar or 
schizoaffective disorder were excluded. Patients treated with ECT in an earlier 
episode were excluded from evaluation and analysis. Diagnosis was based on clinical 
observation during a routinely drug-free period. If patients received more than 1 
course of ECT, only the first course was reviewed.
The ECT was administered with a brief-pulse, constant-current apparatus (Thymatron 
DGx, Somatics, Lake Bluff, Ill.). Seizure threshold was determined during the first 
session with stimulus titration. If the starting stimulus dose failed to elicit a seizure 
of at least 25 seconds’ duration measured with the cuff method, stimulus charge 
was increased according to the titration schedule, and the patient was restimulated 
after 30 seconds.
Seizure threshold was defined as the stimulus dosage that elicited a seizure for at 
least 25 seconds according to the cuff method. For the second treatment, the stimulus 
dosage was set at 1.5 times the initial seizure threshold for bilateral treatment. For 
unilateral treatment, the stimulus dosage was set at 2.5 times the seizure threshold. 
During the course of ECT, stimulus dosage settings were adjusted upward to maintain 
a seizure duration of at least 25 seconds as measured with the cuff method.
Patients were initially treated with right unilateral ECT. Patients were crossed over 
to bilateral ECT if response was inadequate after 6 treatments. Patients in a critical 
condition started with bilateral ECT.
Patients were treated twice weekly until recovery or no progress during at least 10 
bilateral treatments. Clinical evaluation of depressive symptoms was performed each 
week using the Montgomery-Asberg Depression Rating Scale, and scores on the 17-
item version of the Hamilton Rating Scale for Depression (HAM-D) were obtained 1 
to 3 days prior to ECT and 1 to 3 days after treatment termination.
2
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Patients were withdrawn from all psychotropic medication before ECT and were 
maintained medication free during the course of ECT. In case of severe agitation, 
incidental use of haloperidol was allowed.
Patients were classified as responders when their HAM-D score showed a reduction 
of at least 50% posttreatment compared to pretreatment. Patients were classified 
as being in full remission when their posttreatment HAM-D scores were 7 or less.
Prior to ECT, resistance to treatment with a TCA and lithium during a depressive 
episode was evaluated. Adequate treatment was defined as 4 weeks taking a pre- 
defined plasma level of a TCA; nonresponders had lithium added to the medication, 
and the minimal duration of the lithium addition was 3 weeks with a plasma level of 
at least 0.6 mmol/L.
Statistical Analysis
Primary outcome criterion was defined as the mean difference in HAM-D score before 
and after ECT treatment for patients who received adequate treatment with a TCA and 
lithium compared with patients who did not receive adequate treatment with a TCA 
and lithium. Independent samples t test was used to analyze this primary outcome 
criterion.
Fisher exact test was used to analyze the differences in response rate to ECT and 
remission rate between patients who received adequate treatment with a TCA and 
lithium and patients who did not receive adequate treatment with a TCA and lithium. 
Statistical significance was defined as p < 0.05. All analyses were carried out using 
SPSS version 13.0 (SPSS Inc., Chicago, Ill.).
RESULTS
The patient sample consisted of 104 inpatients meeting DSM-IV criteria for depressive 
disorder. Eight patients were excluded because it was not known if they received a 
TCA and lithium prior to ECT. Three patients were excluded because they had been 
previously treated with ECT, and 7 patients were excluded because their HAM-D score 
before ECT was not known. The remaining 86 patients were included for analysis.
Table 1 presents the demographic and clinical characteristics for the total patient 
sample and as a function of inadequate and adequate treatment with a TCA and 
lithium prior to ECT. Thirty patients received inadequate treatment with a TCA 
and lithium, whereas 56 patients received adequate treatment with a TCA and 
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lithium and were classified as medication treatment failures to a TCA and lithium. 
A comparison of both groups revealed no significant differences with regard to age 
and psychotic depression. Patients with adequate treatment with a TCA and lithium 
had a significantly longer duration of current depressive episode (p=0.03) compared 
with the inadequately pretreated patients.
 
Table 1. Demographic and clinical characteristics for the total patient sample and as a function of 




With a TCA and 
Lithium
Inadequate 
treatment With a 
TCA and Lithium
Characteristic (N = 86) (N = 56) (N = 30)
Age, mean (SD), y 54.9 (12.7) 54.6 (11.9) 55.5 (14.3)
Female, N (%) (SD) 60 (71) (5) 19 (66) (5) 24 (80) (4)
Psychotic, N (%) (SD) 37 (43) (5) 25 (45) (5) 12 (40) (5)
Length of index episode, mean (SD), mo  18.6 (12.6) 20.8 (11.9) 14.5 (12.9)
Pre-ECT HAM-D score, mean (SD)  28.1 (8.1) 27.7 (7.6) 28.9 (9.0)
Post-ECT HAM-D score, mean (SD)  10.7 (7.8) 11.4 (8.1) 9.3 (7.3)
Abbreviations: HAM-D = Hamilton Rating Scale for Depression, TCA = tricyclic antidepressant.
 
Treatment Effects
According to the primary outcome criterion, patients with adequate treatment with 
a TCA and lithium had a mean difference in HAM-D score pre-ECT and post-ECT of 
16.4 compared to a mean difference in HAM-D score of 19.5 in the patient group with 
inadequate treatment with a TCA and lithium. This inequality in difference in mean 
HAM-D scores was not significant (p =0.2).
Again, neither response nor remission was influenced by adequate pretreatment with 
a TCA and lithium (p=0.3 and p=0.3, respectively). Response to ECT after adequate 
treatment with a TCA and lithium addition was 67% and remission was 39% compared 
to inadequate treatment with a response to ECT of 77% and remission of 50%. Only 
16 patients were treated with right unilateral ECT; the remaining 70 patients were 
treated with or switched to bilateral ECT.
DISCUSSION
In the present study sample, resistance to adequate pharmacotherapy with a TCA 
and lithium addition appears to be unrelated to both the primary outcome criterion 
2
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(mean difference in HAM-D score pre-ECT and post-ECT treatment) and the secondary 
outcome criterion (response and remission to subsequent ECT). This is in accordance 
with several previous studies (11-13) but in contrast with others (8,9,22).
Different staging methods can be used to assess levels of treatment resistance 
in depression (23). We used a rigorous definition of medication resistance. All 
of our patients were inpatients. Diagnosis was ascertained during a routinely 
psychopharmacologic drug-free observation period of at least 1 week. Those patients 
belonging to the medication-resistant group all had at least 4 weeks of adequate 
plasma levels with a TCA. Doses of TCAs were routinely adjusted to obtain adequate 
plasma levels, which were monitored weekly. With lithium addition, the dose was 
adjusted in order to achieve a lithium level of 0.6 to 1.0 mmol/L for at least 3 weeks.
Baseline psychotropic medication use is mostly quantified with the ATHF (9,24). This 
is a clinician-rated instrument to assess treatment resistance. The cut-off point for 
treatment resistance is a score 3 or more. This score is already achieved when treated 
with an adequate dosage of a single SSRI for 4 weeks, which would probably not 
be considered as a “strong” antidepressant trial by many clinicians. No criterion for 
treatment adherence or accuracy of the diagnosis is required. Moreover, the strategy 
of a TCA with lithium addition is considered to be very efficacious (19-21).
The accuracy of diagnosis in our sample was greatly enhanced by our routine drug-
free observation period before ECT. This procedure benefits the selection of patients 
suitable for ECT. This is in contrast with previous reports in which details about patient 
selection were not disclosed (8,9).
Psychotically depressed patients have a significantly higher difference in HAM-D 
score (22) pre-ECT and post-ECT compared to nonpsychotic depressed patients (13, 
p < 0.001); this is in accordance with the consideration that psychotically depressed 
patients have a superior response rate with ECT relative to nonpsychotic patients 
(25,26).
It seems reasonable that patients with more difficult-to-treat illness will respond less 
well to all subsequent treatments, ECT included; however, the greater efficacy of ECT 
in psychotic depression (generally viewed as the more severe form of depression) 
argues against this.
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In the present study, comparison of the group with adequate treatment with a 
TCA and lithium and the group with inadequate treatment revealed no significant 
differences regarding age, sex, psychotic depression, and pre-ECT HAM-D score. 
Patients adequately treated with a TCA and lithium had a significantly longer duration 
of index episode (p=0.03) compared to patients who were treated inadequately with 
a TCA and lithium; this difference has also been reported in previous trials (9,10,12). 
A reason for this difference could be the fact that some time is needed to adjust a TCA 
and lithium to an adequate dosage for each individual.
A previous study used predominantly unilateral ECT (8), whereas in the present study 
only 16 patients were solely treated with unilateral ECT, and the remaining 70 patients 
were started directly with bilateral ECT or started with unilateral ECT but were 
switched to bilateral ECT. Bilateral ECT is considered to be the most effective electrode 
placement of ECT; the unilateral placement and dosing used in the present trial are 
considered to be less effective (22,27). Our patients were not randomly assigned to 
electrode placement for this trial, and conclusions about electrode placement and 
efficacy are therefore not permitted. Nevertheless, the large percentage of patients 
treated with bilateral ECT in this trial can also contribute to the efficacy of ECT since 
bilateral ECT is considered to be the most efficacious electrode placement.
Limitations
While the criteria used in the ATHF to rate medication resistance are based on data 
from efficacy trials and expert judgment, these criteria are arbitrary. It is not known to 
what extent imposing more stringent cut-offs (such as requiring a minimum treatment 
duration of 6–8 weeks to define an adequate trial) would have altered the findings 
of this study. Furthermore, the 2 groups had an unequal sample size, and both had a 
relatively small sample size, which also could have influenced the results.
CONCLUSION
In the present study, sample resistance to adequate pharmacotherapy with a TCA and 
lithium appears to be unrelated to the primary outcome criterion (mean difference 
in HAM-D score pre-ECT and post-ECT treatment for patients who received adequate 
treatment with a TCA and lithium compared to patients who did not receive adequate 
treatment with a TCA and lithium) and response or remission to subsequent ECT. 
Moreover, the concept of “medication resistance” as defined by arbitrary (ATHF) 
criteria is irrelevant in the decision for a trial of ECT in patients with severe depressive 
illness, whether psychotic or nonpsychotic.
2
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It is encouraging that even in severely depressed inpatients who have failed to respond 
to a TCA and lithium, ECT can be an effective treatment. Patients with a depressive 
disorder not responding to a strong antidepressant trial (adequate treatment with a 
TCA and lithium) can still largely benefit from subsequent ECT.
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Failure to respond to antidepressants probably is the most common indication for 
electroconvulsive therapy (ECT). The literature seems to be divided as to whether 
medication resistance has a negative influence on the efficacy of subsequent ECT. 
Therefore, we performed a systematic review to investigate the effect of previous 
pharmacotherapy failure on the efficacy of ECT. Relevant cohort studies were 
identified from systematic search of the PubMed electronic database. Seven studies 
were included in this meta-analysis: the overall remission rate amounts to 48.0% 
(281/585) for patients with and 64.9% (242/373) for patients without previous 
pharmacotherapy failure. An exact analysis with the Mantel-Haenszel method (fixed 
effect model) shows a reduced efficacy of ECT in patients that received previous 
pharmacotherapy (OR, 0.52; 95% confidence interval [CI], 0.39-0.69). In conclusion, the 
efficacy of ECT is significantly superior in patients without previous pharmacotherapy 
failure as compared with medication-resistant patients. Because this finding is based 
on observational studies, it might be caused by a confounding factor, for example, the 
presence of psychotic features or the duration of the index episode. Electroconvulsive 
therapy seems to be an effective treatment for severely depressed patients as well 
as for patients with previous pharmacotherapy failure.
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INTRODUCTION
Before the introduction of antidepressants, electroconvulsive therapy (ECT) was 
recognized as the most effective treatment for major depression (1). Early studies 
report that 80% to 90% of depressed patients responded to ECT. Widespread 
use of antidepressant pharmacotherapy has changed the population of patients 
that currently receive ECT for major depression. Nowadays, failure to respond to 
antidepressants is probably the most common indication for ECT. More recent studies 
found that depressed patients who did not respond to antidepressants have lower 
remission rates with ECT compared with patients who did not receive adequate 
treatment with antidepressants (2-4). Other studies found no difference in response 
to ECT between patients with and without previous pharmacotherapy failure (5-9).
If antidepressant-refractory patients indeed show a decreased efficacy of ECT, this 
may have consequences for the administration of ECT in these patients. However, 
the opinions seem to be inconclusive as to whether medication resistance has a 
negative influence on the efficacy of subsequent ECT. Therefore, we performed a 
systematic review to investigate the influence of previous pharmacotherapy failure 
on the response to subsequent ECT.
METHODS
Inclusion and Exclusion Criteria
Prospective cohort studies including subjects who were treated with ECT for major 
depressive disorder were included. The studies had to use accepted diagnostic criteria 
for major depression, that is, Diagnostic and Statistical Manual of Mental Disorders, 
Third Edition (DSM-III) (R), DSM-IV, or Research Diagnostic Criteria, and had to report 
the outcome according to a valid depression rating scale, that is, the Hamilton Rating 
Scale for Depression (HAM-D) (10) or the Montgomery-Asberg Depression Rating Scale 
(11). All patients had discontinued antidepressant drugs at least 3 days before and 
during the ECT course. Patients in the selected studies were diagnosed with major 
depression with or without psychotic features. Medication resistance was defined 
according to the Antidepressant Treatment History Form (ATHF) developed in 1990 
by the Columbia University Group (2,3). For patients with psychotic depression, the 
adequacy of both antidepressant and antipsychotics were assessed. The criteria 
involved separate standards for patients with psychotic depression relative to 
nonpsychotic depression.
Literature Search
The search was conducted in June 2009.
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Relevant cohort studies were identified from systematic searches of the PubMed 
electronic database. The search terms were ECT[All Fields] AND (“depressive 
disorder”; [MeSH Terms] OR (“depressive” [All Fields] AND “disorder” [All Fields]) OR 
“depressive disorder” [All Fields]) AND (“antidepressive agents” [MeSH Terms] OR 
(“antidepressive” [All Fields] AND “agents” [All Fields]) OR “antidepressive agents” [All 
Fields] OR “antidepressant” [All Fields] OR “antidepressive agents” [Pharmacological 
Action]) AND ((“pharmaceutical preparations” [MeSH Terms] OR (“pharmaceutical” 
[All Fields] AND “preparations” [All Fields]) OR “pharmaceutical preparations” [All 
Fields] OR “medication” [All Fields]) AND resistance [All Fields]) AND (remission [All 
Fields] OR response [All Fields]) AND (“humans” [MeSH Terms] AND English[lang]).
A manual search of the references of the included studies was also performed. A total 
of 21 studies were identified using this search strategy.
Clinical Outcomes
Because most of the patients with severe major depression will show some response 
to ECT, the response criterion (≥50% reduction on the HAM-D) may not be the most 
appropriate measure of the efficacy of ECT, and remission may be more suitable (5).
In the current review, the primary outcome criterion was the remission rate. Remission 
is defined as either a score 7 or less on the 17-item HAM-D, a score of 10 or less on the 
24-item HAM-D, or a score of 8 or less on the Montgomery-Asberg Depression Rating 
Scale, with preference given in that order if more than 1 scale was reported. In 1 
study, a score of 9 or less on the 24-item HAM-D was used as a remission criterion (2).
Quality Assessment of the Studies
Each article was assessed by 3 of the authors (W.T.H., T.K.B., and W.W.vdB.) with the use 
of an assessment form compiled by the Dutch Institute for Healthcare Improvement 
(CBO). This form was designed to evaluate cohort studies for the development of 
evidence-based guidelines. The form abstracts data on the adequacy of the definition 
of the cohort, selection bias, blinded outcome assessment, confounders, prognostic 
factors, and clinical outcomes.
Statistical Analysis
Differences in remission rates between patients with previous pharmacotherapy 
failure versus patients without previous pharmacotherapy failure are expressed 
as odds ratios (ORs). Exact P values and confidence intervals (CIs) were calculated 
with the Mantel-Haenszel method (fixed effect model). Heterogeneity across studies 
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was assessed using the Cochran Q test and I2 statistic. Pooled ORs were calculated 
using fixed effects meta-analysis. Statistical analyses were performed using SPSS for 
Windows, version 15.0 (SPSS Inc, Chicago, Ill).
RESULTS
A total of 21 studies were identified by our search strategy. Seven of these did not 
address the issue of this meta-analysis and were excluded. Another 4 studies were 
not included because they focused on relapse (12-15) or continuation therapy after 
successful ECT (16,17). The remaining 8 studies were assessed using the Dutch 
Institute for Healthcare Improvement form: of these, 1 study was excluded because 
it was a retrospective study (5). and another was excluded because the remission 
rate was lacking (7). One of the reviewers suggested assessing 5 other prospective 
trials that were left out in the initial search strategy (18-22). However, because only 
Sackeim et al (18) provided remission percentages both for medication-resistant 
and non-medication-resistant patients, this study was added to the meta-analysis. 
Thus, finally, 7 studies (2-4,6,8,9,18) were included in this meta-analysis. The included 
studies comprise a total of 585 patients with previous pharmacotherapy failure and 
373 patients without medication resistance. The overall remission rate amounts 
to 48.0% (281/585) for patients with previous pharmacotherapy failure and 64.9% 
(242/373) for patients without previous pharmacotherapy failure. The Cochran Q test 
(χ2 = 9.10, df = 6, p= 0.17) and I2 statistic (34.1% CI, 0%-72%) suggest nonsignificant 
heterogeneity. Table 1 gives the description of the included studies and estimated 
ORs of remission of the sample with previous pharmacotherapy relative to the 
sample without medication resistance. An exact analysis shows a reduced efficacy 
of ECT in patients that received previous pharmacotherapy (OR, 0.58; 95% CI, 0.44-
0.75). A second analysis calculating a weighted OR showed a similar result (OR, 0.52; 
95% CI, 0.39-0.69). Figure 1 shows the plots of the ORs after natural logarithmic 
transformation.
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Table 1. Description of the included studies and estimated ORs of remission in medication-resistant 
versus non medication-resistant patients
No. Patients Remission Rate No. Patients Remission Rate
With Adequate With Adequate With Inadequate With Inadequate
Pretreatment Pretreatment (%) Pretreatment Pretreatment (%) OR 95% CI
Prudic 
19902   24 42    29 69 0.32 0.1-1.00
Prudic 
19963   65 63    35 91 0.16 0.04-0.58
Sackeim 
200018   46 37    34 65 0.32 0.13-0.81
van den 
Broek 20046   48 44    37 41 1.14 0.48-2.72
Dombrovski 
20054 178 48 150 65 0.51 0.33-0.80
Rasmussen 
20078 168 63    58 71 0.69 0.36-1.32
Heijnen 





Figure 1. Plot of the ORs of response to ECT in patients with previous pharmacotherapy failure relative 
to patients without pretreatment per study, with 95% CI, aft er natural logarithmic transformation
                      
Willemijn Binnenwerk.indd   40 18-3-2020   13:54:34
41
Treatment failure and response to ECT: a meta-analysis
DISCUSSION
This meta-analysis provides evidence that the efficacy of ECT is significantly superior 
in patients without previous pharmacotherapy failure as compared with medication-
resistant patients. However, 3 of the 7 studies did not individually show a significant 
difference between the 2 patient samples: this requires some discussion. All studies 
that did show a difference were conducted by the same group (Columbia University, 
New York); these 4 studies had a similar methodology, albeit that in two of these 
studies (2,18) bipolar depressives were included, and in another study (3) only 
patients with non-psychotic depression were selected.
In these studies, a substantial proportion of the patients were treated with right 
unilateral ECT, which is nowadays considered a less effective form of ECT unless an 
electrical stimulus of 6x seizure threshold is used. However, these studies did not 
use high-dose right unilateral ECT. This may have influenced the results, but it is 
not possible to adjust for this difference. Furthermore, patients were allowed to use 
lorazepam during the ECT course. Both latter factors could have contributed to the 
less favorable results, especially in the adequately pretreated group. In 2 studies 
(6,9) incidental use of haloperidol as concurrent medication during the ECT course 
was allowed; however, haloperidol probably does not interfere with the efficacy of 
ECT. The study of van den Broek et al (6) is the only one to report a (nonsignificant) 
higher efficacy of ECT in the sample with previous pharmacotherapy failure 
(Fig.1) (6). Differences between study results may be due to chance; however, with 
heterogeneity, the difference between the results of the various studies is larger than 
one would expect by chance. A possible explanation for the heterogeneity could be 
that some studies (2-4,18) used the research diagnostic criteria for major depression, 
whereas others used the DSM-IV criteria (6,8,9). Furthermore, 2 different versions of 
the HAM-D (and 2 different definitions of remission) were used: in most studies, the 
24-item version of the HAM-D was used (2-4,8,18) whereas 2 studies used the 17-
item version (6,9). Another relevant issue is the proportion of patients with psychotic 
depression in the selected studies. Two studies excluded patients with psychotic 
depression (3,8), whereas in the studies of Dombrovski et al (4) and Sackeim et al (18), 
a minority (resp 28% and 36%) of patients showed psychotic features, whereas in 
the remaining 3 studies, almost 50% of the sample had psychotic depression (2,6,9). 
Because patients with psychotic depression show a substantially higher response 
rate to ECT (23,24), the proportion of patients with psychotic depression is likely to 
influence study results. The impact of treatment failure on the outcome of psychotic 
depression has not been studied previously.
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Limitations of this meta-analysis
Meta-analysis, a systematic approach for combining the results of relevant studies to 
draw conclusions about a body of research, has been frequently applied to randomized 
controlled trials (RCTs). However, in some situations, a randomized controlled trial is 
not feasible, and only data from observational studies are available (25). This applies 
to medication resistance. Several clinical features determine whether a depressed 
patient is treated with pharmacotherapy or receives ECT directly. This choice depends 
on a patients’ age, somatic condition, the severity of the depressive episode, the 
presence of psychotic features, and fluid and food intake. However, a meta-analysis 
of observational studies has inherent biases and differences in study designs. Several 
of these differences have been mentioned above. The staging method of treatment 
resistance in depression forms an additional limitation. Baseline psychotropic 
medication use is mostly quantified with the Antidepressant Treatment History 
Form (2,3).This is a physician-rated instrument to assess treatment resistance. The 
cutoff point for treatment resistance is a score 3 or less. This score is already attained 
when treated with an adequate dosage of a selective serotonin reuptake inhibitor for 
4 weeks, which would probably not be considered a strong antidepressant trial by 
many physicians.
CONCLUSIONS
The efficacy of ECT seems to be superior in patients without previous pharmacotherapy 
failure compared with adequately pretreated patients. Because this finding is based 
on observational studies, it might be caused by a confounding factor, for example, 
the presence of psychotic features or the duration of the index episode.
Furthermore, the overall remission rate for patients with previous pharmacotherapy 
failure is encouraging (48%). Therefore, ECT seems to be an effective treatment for 
severely depressed patients as well as for patients with previous pharmacotherapy 
failure.
Optimal administration of ECT is very important especially in medication-resistant 
patients to consider bilateral ECT, to refrain from benzodiazepines as concomitant 
medication, and to continue the ECT course as long as the patient improves.
Willemijn Binnenwerk.indd   42 18-3-2020   13:54:34
43
Treatment failure and response to ECT: a meta-analysis
REFERENCES
1. Fink M. History of convulsive therapies. In: Fink M, ed. Convulsive Therapy: Theory and 
Practice. New York, NY: Raven Press; 1979:5-17.
2. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to 
electroconvulsive therapy. Psychiatry Res. 1990;31:287-296.
3. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-
term clinical response to ECT. Am J Psychiatry. 1996;153:985-992.
4. Dombrovski AY, Mulsant BH, Haskett RF, et al. Predictors of remission after electroconvulsive 
therapy in unipolar major depression. J Clin Psychiatry. 2005;66:1043-1049.
5. Pluijms EM, Birkenhäger TK, Huijbrechts IP, et al. Influence of resistance to antidepressant 
pharmacotherapy on short-term response to electroconvulsive therapy. J Affect Disord. 
2002;69:93-99
6. van den Broek WW, de Lely A, Mulder PG, et al. Effect of antidepressant medication 
resistance on short-term response to electroconvulsive therapy. J Clin Psychopharmacol. 
2004;24:400-403.
7. Husain SS, Kevan IM, Linnell R, et al. Electroconvulsive therapy in depressive illness that 
has not responded to drug treatment. J Affect Disord. 2004;83:121-126.
8. Rasmussen KG, Mueller M, Knapp RG, et al. Antidepressant medication treatment failure 
does not predict lower remission with ECT for major depressive disorder: a report from the 
consortium for research in electroconvulsive therapy. J Clin Psychiatry. 2007;68:1701-1706.
9. Heijnen WT, van den Broek WW, Birkenhäger TK. Treatment failure with a tricyclic 
antidepressant followed by lithium addition and response to subsequent electroconvulsive 
therapy. J Clin Psychiatry. 2008;69:1887-1891.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br 
J Psychiatry. 1979;134:382-389.
12. Rasmussen KG, Mueller M, Rummans TA, et al. Is baseline medication resistance associated 
with potential for relapse after successful remission of a depressive episode with ECT? Data 
from the consortium for research in electroconvulsive therapy (CORE). J Clin Psychiatry. 
2009;71:232-237.
13. van den Broek WW, Birkenhäger TK, Mulder PG, et al. Imipramine is effective in 
preventing relapse in electroconvulsive therapy-responsive depressed inpatients with 
prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial. J Clin 
Psychiatry. 2006;67:263-268.
14. Devanand DP, Sackeim HA, Prudic J. Electroconvulsive therapy in the treatment-resistant 
patient. Psychiatr Clin North Am. 1991;14:905-923.
15. Sackeim HA, Prudic J, Devanand DP, et al. The impact of medication resistance and 
continuation pharmacotherapy on relapse following response to electroconvulsive therapy 
in major depression. J Clin Psychopharmacol. 1990;10:96-104.
16. Shapira B, Gorfine M, Lerer B. A prospective study of lithium continuation therapy in 
depressed patients who have responded to electroconvulsive therapy. Convuls Ther. 
1995;11:80-85.
17. Sackeim HA. Continuation therapy following ECT: directions for future research. 
Psychopharmacol Bull. 1994;30:501-521.
3
Willemijn Binnenwerk.indd   43 18-3-2020   13:54:34
44
Chapter 3
18. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized double-blind 
comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus 
intensities. Arch Gen Psychiatry. 2000;57:425-434.
19. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the 
prevention of relapse following electroconvulsive therapy: a randomized controlled trial. 
JAMA. 2001;285:1299-1307.
20. Prudic J, Olfson M, Marcus SC, et al. Effectiveness of electroconvulsive therapy in 
community Settings. Biol psychiatry. 2004;55:301-312.
21. Sackeim HA, Prudic J, Nobler MS, et al. Effects of pulse width and electrode placement 
on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimulation. 
2008;1:71-83.
22. Sackeim HA, Dillingham EM, Prudic J, et al. Effect of concomitant pharmacotherapy on 
electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen 
Psychiatry. 2009;66:729-737.
23. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic 
depressed patients: a report from CORE. J ECT. 2001;17:244-253.
24. Birkenhäger TK, Pluijms EM, Lucius SA. ECT response in delusional versus nondelusional 
depressed inpatients. J Affect Disord. 2003;74:191-1
25. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in 
epidemiology. JAMA. 2000;283:2008-2012.
Willemijn Binnenwerk.indd   44 18-3-2020   13:54:34
45
Treatment failure and response to ECT: a meta-analysis
3
Willemijn Binnenwerk.indd   45 18-3-2020   13:54:34
Willemijn Binnenwerk.indd   46 18-3-2020   13:54:34
Chapter 4
Eff icacy of electroconvulsive therapy 
in bipolar versus unipolar major 
depression: a meta-analysis
   Bram Dierckx
   Willemijn T.C.J. Heijnen
   Walter W. van den Broek
   Tom K. Birkenhäger
   Bipolar disorders 2012;14:146-150




Objective: Bipolar major depression differs considerably from unipolar major 
depression with regard to the efficacy of treatment with antidepressants. In bipolar 
depression, response to treatment with antidepressants is disappointing. Whether 
response to electroconvulsive therapy (ECT) differs between bipolar and unipolar 
depression remains unclear. Therefore, this systematic review investigates the relative 
efficacy of ECT in both forms of depression.
Methods: Relevant cohort studies were identified from a systematic search of the 
PubMed electronic database. Six studies were included in this meta-analysis.
Results: In this meta-analysis, the overall remission rate was 50.9% (n=402/790) 
for patients with unipolar depression and 53.2% (n=168/316) for patients with 
bipolar major depression. A pooled odds ratio (OR) and confidence interval (CI) were 
calculated using random-effects meta-analysis with the Mantel–Haenzel method. This 
analysis shows similar efficacy of ECT in patients with unipolar and bipolar depression 
(OR = 1.08, 95% CI: 0.75–1.57).
Conclusion: ECT appears to be equally effective for both bipolar and unipolar 
depression and the remission rates are encouraging, especially for bipolar depression.
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INTRODUCTION
Although electroconvulsive therapy (ECT) is widely used for the management of 
severe and refractory depression (1), its utility in bipolar depression has not been 
well studied. This is surprising since there are indications that major differences exist 
in treatment response between unipolar and bipolar depression (2, 3). For example, 
in a study comparing the addition of paroxetine or imipramine to lithium therapy with 
placebo in bipolar depression, neither the paroxetine-treated nor the imipramine-
treated group showed any significant benefit over the placebo group (4). More 
recently, antidepressant add-on in bipolar depression was again shown to be no more 
efficacious than optimized mood stabilizer monotherapy (5). Moreover, treatment 
with antidepressants in bipolar depression carries the risk of manic switches (6).
ECT is routinely employed for the treatment of severe and treatment-resistant major 
depression. However, ECT treatment response differences between unipolar and 
bipolar depression remain unclear. One study reported that ECT had equivalent 
efficacy in both types of depressive patients (7) and similar results were reported 
by others (8-10). However, another retrospective study reported that patients with 
unipolar depression were more likely to show marked improvement than patients 
with bipolar depression (11). Similar results were reported in a study investigating 137 
patients with unipolar depression and 113 with either bipolar I or II disorder; unipolar 
patients had higher remission rates than both bipolar I and II disorder patients (3).
Since major differences exist in antidepressant treatment response between bipolar 
and unipolar depression, assessing the efficacy of ECT in bipolar depression is 
clinically relevant.
It remains unclear whether the efficacy of ECT in bipolar depression is comparable 
to its efficacy in unipolar depression. Therefore, this systematic review investigates 
the relative efficacy of ECT in both forms of depression.
METHODS
Inclusion and exclusion criteria
We included prospective and retrospective cohort studies comparing the efficacy 
of ECT in patients suffering from unipolar major depressive disorder to patients 
with bipolar major depression. Studies had to use accepted diagnostic criteria for 
major depression [i.e., the Diagnostic and Statistical Manual of Mental Disorders, 
third edition (DSM-III), DSM-IV, or Research Diagnostic Criteria] and had to report the 
4
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outcome according to a valid depression rating scale [i.e., the Hamilton Rating Scale 
for Depression (HAM-D) (12) or the Montgomery–Åsberg Depression Rating Scale (13)].
Literature search
The search was conducted in June 2010. Relevant studies were identified from 
systematic searches of the PubMed electronic database. The search terms used were 
[ECT (all fields) or electroconvulsive therapy (all fields)] and unipolar (all fields), bipolar 
(all fields), and depression (all fields). Studies prior to 1980 were omitted, thereby 
allowing the selection of studies using the DSM-III or DSM-IV criteria.
Since ECT techniques have changed considerably in the last few decades with regard 
to stimulus form (brief-pulse instead of sine wave), stimulus dosing, and choice of 
anaesthetic agent, a manual search of the reference lists of the included studies was 
also performed. This search strategy identified a total of 105 studies.
Clinical outcomes
Since most patients with severe depression will show some response to ECT, the 
response criterion (≥ 50% reduction on the HAM-D score) may lack the sensitivity 
needed to detect differences in treatment efficacy between unipolar and bipolar 
depression; therefore, we opted to use the remission criterion instead.
In the current review, the primary outcome criterion was the remission rate. Remission 
was defined as either a score ≤ 7 on the 17-item HAM-D or a score ≤ 10 on the 24-item 
HAM-D, with preference given in that order if more than one scale was reported. In 
one study, a score ≤ 11 on the 24-item HAM-D was used as remission criterion (8).
Quality assessment of the studies
Each article was independently assessed by two of the authors (BD and TKB) with 
the use of an assessment form compiled by the Dutch Institute for Healthcare 
Improvement (CBO). The form retrieves data on the adequacy of the definition of 
the cohort, selection bias, blinded outcome assessment, confounders, prognostic 
factors, and clinical outcomes. Study validity is assessed with regard to definition of 
the study samples, the adequacy of the intervention studied, and the use of clearly 
defined outcome criteria, resulting in a general judgement of the studies (14).
Statistical analysis
Differences in remission rates between patients with bipolar or unipolar depression 
disorder are given as odds ratios (ORs) and confidence intervals (CIs). One study 
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reported outcomes for bipolar I and II disorder patients separately (3); therefore, 
to be consistent with the other studies, these two outcomes were merged into one 
bipolar major depression group.
A pooled OR and CI were calculated using both fixed-effects meta-analysis and 
random-effects meta-analysis with the Mantel–Haenzel method. Heterogeneity 
across studies was assessed using Cochran’s Q-test. Statistical analyses were 
performed using SPSS for Windows, version 16.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 105 studies were identified by our search strategy; of these, 94 did not 
address the study topic and were excluded. Another four studies (7, 14-16) were 
excluded because they did not use the HAM-D as an endpoint measure, and one 
additional study (17) was excluded due to lack of information on the remission rate. As 
a result, six studies were included in the meta-analysis (3, 8, 9, 19-21): five studies were 
prospective and one consisted of a chart review (8). The included studies comprised 
a total of 1106 patients, of whom 790 were diagnosed with unipolar depression and 
316 were diagnosed with bipolar depression.
The overall remission rate was 51.5%; for patients with unipolar depression it was 
50.9% (n=402/790) and for patients with bipolar depression it was 53.2% (n=168/316). 
In all six studies, severity of depression at baseline (as measured by the HAM-D) was 
similar when comparing unipolar and bipolar disorder patients (3, 8, 9, 18-20). No 
differences were reported in the occurrence of psychotic symptoms. In four studies, 
bipolar disorder patients presented with a more severe course of illness than unipolar 
patients, as evidenced by an increased number of episodes prior to the current 
episode (3, 18, 19) or by a higher number of hospital admissions (9). In three studies (9, 
18, 19), antidepressant drugs were discontinued at least three days before and during 
the ECT course, two studies (8, 20) did not provide information on concurrent use of 
antidepressants, and in the remaining study (3), concurrent use of antidepressants 
was permitted.
Cochran’s Q-test (χ2=8.8, p=0.1) is indicative of heterogeneity between the studies 
using the more stringent p-level of 10%. Hence, only the results of the random-effects 
model meta-analysis are displayed because it was able to handle the heterogeneity 
between the studies. Table 1 describes the six studies and gives the estimated ORs 
of remission, which show similar efficacy of ECT in patients with unipolar and bipolar 
depression (OR = 1.08, 95% CI: 0.75–1.57). When we omitted the single retrospective 
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study (8) from the analysis, heterogeneity remained present (χ2=8.56, p=0.09). In 
addition, results from the random-eff ects model were similar (OR = 1.12, 95% CI: 0.74–
1.71). Figure 1 shows the plots of the ORs aft er natural logarithmic transformation.
Table 1. Description of the included studies and estimated odds ratios (ORs) of remission in unipolar 
versus bipolar depression
Study Study type Unipolar (n) Bipolar (n) ORa (95% CI)
Bailine et al. 2010 (18) Prospective 170 50 1.13 (0.6–2.2)
Sienaert et al. 2009 (9) Prospective    51 13 2.14 (0.6–7.3)
Medda et al. 2009 (3) Prospective    17 BD-I= 46BD-II = 67 0.28 (0.09–0.80)
Sackeim and Prudic 2005 (20) Prospective 279 54 1.22 (0.7–2.3)
Grunhaus et al. 2002 (8) Chart review 111 20 0.76 (0.3–2.1)
Daly et al. 2001 (19) Prospective 162 66 1.47 (0.8–2.6)
Abbreviations: BD-I = bipolar I disorder; BD-II = bipolar II disorder; CI = confi dence interval.
aReference category: remission in unipolar depression
Figure 1. Plot of the odds ratios of response to electroconvulsive therapy in patients with unipolar versus 
bipolar depression per study, with 95% confi dence interval, aft er natural logarithmic transformation
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DISCUSSION
This meta-analysis provides evidence for the equal efficacy of ECT in unipolar and 
bipolar depression, despite bipolar disorder patients presenting with a more severe 
history of illness in most of the studies (3, 9, 18, 19).
This equal efficacy of ECT in unipolar and bipolar depression is important, since 
bipolar depression is hard to treat due to the limited effects of antidepressant add-on 
therapy and the additional risk of manic switches.
In addition, some clinicians report that patients with bipolar depression need (on 
average) fewer ECT sessions during their ECT course than patients with unipolar 
depression (18, 19). One study (20) showed that, among responders, bipolar disorder 
patients received fewer sessions of ECT (6.2±2.3) than unipolar patients (7.2±2.5). This 
was partially corroborated by another study (9) reporting that patients with bipolar 
depression needed fewer ECT sessions to reach response status. However, there was 
no significant difference in the number of ECT sessions needed to reach the most 
stringent remission criterion (17-item HAM-D score ≤ 7) (9). Although there were too 
few studies to perform a meta-analysis on speed of response, these findings further 
underscore the efficacy of ECT in bipolar depression. This is in addition to the efficacy 
of ECT in treating manic episodes in bipolar disorder, where it ranks as one of the most 
effective therapies for the treatment of severe mania and may be the treatment of 
choice for patients with treatment-resistant mania (21).
One study included in this meta-analysis (3) showed a greater efficacy of ECT in 
unipolar depressed patients, despite the fact that both patient groups had similar 
levels of depressive symptoms at baseline, a similar number of mood episodes in 
their history, and a similar duration of the current episode. In addition, unipolar and 
bipolar disorder patients received a comparable number of ECT sessions and the 
study protocol allowed the use of concomitant psychotropic medication (except 
anticonvulsant mood stabilizers) (3). Although all patients were non-responders to 
at least two regimens of pharmacological therapy, the concomitant pharmacological 
treatment may have slanted the results towards patients with unipolar depression (3).
One study (18) reported remission rates (61% for unipolar depression and 64% for 
bipolar depression) that were superior to the remaining studies. Several details of the 
administration of ECT and patient selection were examined in order to try to explain 
this difference in the efficacy of ECT. In all of the studies, with the exception of the 
study by Medda et al. (3), a substantial proportion of the patients were treated with 
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right unilateral ECT, and only two studies (9, 18) used an electrical stimulus of 6× the 
seizure threshold as standard procedure. Furthermore, Bailine et al. (18) employed 
a minimum duration of ten ECT sessions before concluding non-remission in a 
patient, whereas another study (8) required a minimum duration of six sessions, and 
the remaining studies did not report minimum requirements with regard to the ECT 
course. Therefore, the administration of ECT may have been less optimal in several of 
the other studies, as compared with the study of Bailine et al. (18). The applied criteria 
for remission did not explain the superior remission rate in the study of Bailine et al. 
(18); three studies (18-20) defined remission as a score ≤ 10 on the 24-item HAM-D, 
while two studies (3, 9) used a score ≤ 7 on the 17-item HAM-D. The remaining study 
(8) used a less strict remission criterion of a score ≤ 11 on the 21-item HAM-D.
Study limitations
Meta-analysis is a systematic approach for combining the results of relevant studies 
to draw conclusions about a body of research and is usually applied to randomized 
controlled trials (RCT); however, in some situations a RCT is not feasible (22). Due 
to the nature of the study subject, this is a meta-analysis of observational studies 
and is in contrast to a meta-analysis based on data from RCTs which may result in 
an increased vulnerability towards some form of bias. In the present study, there 
are inherent differences because, in effect, we are comparing two different patient 
groups. Several of these differences have been mentioned above; however, none of 
these are indicative of the bipolar disorder patients in these studies having a less 
severe course of illness or a less severe current episode.
The proportion of patients with psychotic depression is a potential confounding factor 
with regard to the efficacy of ECT, since ECT is particularly effective in patients with 
psychotic depression (23, 24). However, this factor does not appear to have influenced 
the results of this meta-analysis, since in four studies a similar proportion of patients 
in both samples suffered from psychotic depression, and a fifth study controlled for 
this variable in its analysis.
It should also be mentioned that the studies used different methods to ascertain 
the levels of treatment resistance in the participating patients, together with the 
additional problem of defining inclusion criteria that lead to comparable levels of 
treatment resistance being selected for both unipolar and bipolar disorder patients. 
This may be a relevant confounding factor, since previous pharmacotherapy failure 
is reported to reduce remission to subsequent ECT (25). This may have contributed 
to the statistical heterogeneity we observed across the studies.
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CONCLUSIONS
ECT appears to be equally effective for bipolar depression as compared with unipolar 
depression. The remission rates of 50.9% in bipolar depression and 53.3% in unipolar 
depression show that the remission rate to ECT is very similar in both samples. These 
remission rates are encouraging, especially for bipolar depression, since this type of 
major depression often proves to be relatively treatment resistant.
4
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Objective: To investigate whether older age predicts a higher efficacy of 
electroconvulsive therapy (ECT) in severely depressed patients. Also, to analyze 
whether psychomotor disturbance and/or psychotic features might explain the 
potential higher efficacy of ECT in older age.
Method: A total of 96 patients with major depressive disorder treated with bilateral 
ECT were evaluated. The 17-item HAM-D and the MADRS were used to evaluate the 
efficacy of ECT and time to remission, respectively. Psychomotor disturbance was 
defined according the HAM-D.
Results: Middle-aged (MA; 50 to 70 years) and older-aged (OA; ≥70 years) patients 
had a non-significant larger symptom reduction compared with young-aged (YA; <50 
years) patients. Medium effect size was found in favor of MA (d=0.44) and small effect 
size in favor of OA (d=0.30), when compared to YA. Patients with psychotic features 
and patients with psychomotor retardation had a significantly larger symptom 
reduction (p<0.001 and p=0.005, respectively; d=0.88 and d=0.66, respectively). The 
association between age and ECT efficacy is mediated by psychomotor retardation 
(p=.049) and in lesser extent by psychotic features (p=.071).
Conclusion: The results show that psychomotor retardation and psychotic features 
are strong predictors of ECT efficacy and explain the association between age and 
ECT efficacy. Instead of focusing on the age of a patient, clinicians should focus on the 
presence of psychomotor disturbances and psychotic features of depression, when 
considering ECT treatment.
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INTRODUCTION
Electroconvulsive therapy (ECT) is a highly effective treatment in severe major 
depression (UK ECT ReviewGroup, 2003). However, up to 30% of patients fail to 
achieve response (UK ECT ReviewGroup, 2003) and up to 45% of the patients do not 
achieve full remission (Kellner et al., 2010).
Few convincing clinical predictors of efficacy of ECT in major depression are known: 
The absence of medication resistance, the presence of delusions, previous ECT 
treatment and a shorter duration of the index episode (Birkenhager et al., 2003; Loo 
et al., 2011; Petrides et al., 2001). Further, marked psychomotor disturbance (agitation 
and/or retardation) might be a predictor for better ECT efficacy (Buchan et al., 1992; 
Hickie et al., 1996). Another relevant predictor of ECT efficacy might be older age as 
it is reported that ECT is more likely to be effective in older patients (Nordenskjold 
et al., 2012; O’Connor et al., 2001; Spashett et al., 2014; Tew et al., 1999). Apart from 
one study (Nordenskjold et al., 2012), all of the studies included patients with major 
depression exclusively. On the other hand, others failed to find an influence of older 
age on ECT efficacy (Birkenhager et al., 2010; Bloch et al., 2001; Damm et al., 2010). 
However, in two of these studies the population was a mixture of patients with 
major depression, schizophrenia and/or schizoaffective disorder (Bloch et al., 2001; 
Damm et al., 2010). Birkenhäger et al. (2010) found no linear relationship between 
age and ECT efficacy. Two meta-analyses of clinical predictors found an association 
between older age and higher ECT response rates (van Diermen et al., 2018; Haq et 
al., 2015). However, this association was weak and heterogeneity between studies 
was substantial.
Therefore, it is important to investigate whether older age is a predictor of efficacy 
of ECT. Specific symptoms such as the presence of psychotic features and marked 
psychomotor disturbance might be more common in elderly patients (Brodaty et al., 
1997; O’Connor et al., 2001). Psychotic features in major depression are a convincing 
predictor for higher ECT efficacy (Birkenhager et al., 2003; Loo et al., 2011; Petrides 
et al., 2001) and the same might apply to marked psychomotor disturbance (Buchan 
et al., 1992; Hickie et al., 1996). Therefore, the hypothesized higher efficacy of ECT in 
older depressed patients might be partly explained by the presence of one or both 
of these symptoms.
Aims of the study
The primary aim of the present study is to test the hypothesis that older age predicts 
higher ECT efficacy and a shorter time to remission in severely depressed patients.
5
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Next, it is important to identify possible underlying mechanisms, like specific 
depressive symptoms. Therefore, the secondary aim is to analyze whether 
psychomotor disturbance and/or psychotic features mediate the relationship 
between age and ECT efficacy.
METHODS
Patients
The PROSPECT cohort is a prospective study of depressed patients treated with ECT 
at the Department of Psychiatry of the Erasmus Medical Center from January 2006 up 
to date. Patients are included in the PROSPECT cohort if they meet the DSM-IV criteria 
(American Psychiatric Association, 1994) for major depressive disorder (MDD) with or 
without psychotic features and have a score of ≥ 17 on the 17-item Hamilton Rating 
Scale for Depression (HAM-D) (Bech et al., 1986). Diagnoses are based on clinical 
observations during a routine drug-free period. A diagnosis of mood congruent 
psychotic depression is made solely when the patient shows definite mood-congruent 
delusions.
A subset of adult PROSPECT patients (18 years and older) was selected for the current 
analyses. We excluded all patients with alcohol or drug dependence, a diagnosis of 
schizophrenia, schizoaffective disorder, bipolar disorder, psychotic disorder not 
otherwise specified, obsessive-compulsive disorder, dementia, and other neurological 
disorders. To avoid electrode placement acting as a confounding factor, only patients 
treated with bilateral ECT were selected. Although a recent randomized trial found 
no difference in efficacy between high dose-unilateral and bitemporal ECT in MDD 
(Semkovska et al., 2016), generally, bilateral ECT is considered more effective than 
right unilateral ECT (UK ECT ReviewGroup, 2003). To avoid bias, of patients receiving 
more than one ECT course during this period, only the first treatment course was 
included in the sample.
The study was conducted in accordance with the latest version of the Declaration of 
Helsinki and informed consent of the participants was obtained after the nature of the 
procedures had been fully explained. Since all data were obtained as part of standard 
psychiatric care, medical ethical review was not deemed necessary.
For the purpose of our analyses, patients were divided into three age groups to 
investigate the impact of age: young-aged (YA) patients: <50 years, middle-aged (MA) 
patients: ≥ 50 and <70 years, and old aged (OA) patients: ≥ 70 years. Since a recent 
meta-analysis showed a curvelinear relationship between age and ECT efficacy (van 
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Diermen et al., 2018), this categorization allows us explore non-linear relationships. 
We suppose a decreased efficacy of ECT in patients < 50 years.
This categorization was chosen because it can be considered as clinically relevant 
categories corresponding to a younger age group, a middle age group and an older 
age group. HAM-D items were used as indicator of the presence of unique symptoms. 
A score of 2, 3 or 4 on the HAM-D items 8 (psychomotor retardation) or 9 (psychomotor 
agitation), was classified as the presence of the symptom. A score of 0-1 on item 8 
represents normal speech and thought or slight retardation and a score of 2-4 stands 
for at least obvious retardation at interview. A score of 0-1 on item 9 represents no 
agitation or fidgetiness and score of 2-4 stands for at least obvious restlessness 
(playing with hands, hair, moving about).
Electroconvulsive therapy
Patients were withdrawn from all psychotropic medication at least five days prior to 
the first ECT treatment and the majority of patients were maintained medication-free 
during the course of ECT. Because several patients participated in a study involving 
nortriptyline, 16 patients were treated with nortriptyline during the course of ECT. 
Approximately 3 patients in the YA group (23%), 9 patients in the MA group (18%) 
and 4 patients in the OA group (12%) received nortriptyline during ECT. In case of 
severe agitation, incidental use of haloperidol was allowed, whereas the use of 
benzodiazepines during ECT was not allowed.
All patients were treated with bilateral ECT. ECT was administered twice weekly with 
a brief-pulse constant current apparatus (Thymatron, Somatics, IL, USA). Seizure 
threshold, defined as the stimulus dosage that elicited a seizure of at least 25 s 
according to the cuff method, was determined during the first session with empirical 
stimulus titration. If the starting stimulus dose failed to elicit a seizure of at least 25 
s, stimulus charge was increased according to the titration schedule and the patient 
was restimulated after 30 s. For the second treatment, the stimulus dosage was set 
at 1.5 times the seizure threshold. During the course of ECT, stimulus dosage settings 
were adjusted upward to maintain seizure duration of at least 25 s as measured with 
the cuff method.
Anesthesia was achieved after premedication with 0.2 mg glycopyrrolate, with 
intravenous administration of etomidate (0.2 mg/kg), alfentanil (7-10 microgram/
kg) and succinylcholine (0.5-1.0 mg/kg). During the procedure, patients were 
ventilated by mask until the resumption of spontaneous respiration. Physiological 
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monitoring included pulse oximetry, non-invasive blood pressure measurement, 
electrocardiogram and electroencephalogram. The number of ECT treatments 
was determined by clinical observation; a minimum of 10 bilateral treatments was 
required before evaluation as a non-responder. ECT was continued until patients 
were either asymptomatic or had not shown any further improvement as measured 
by the HAM-D over the course of three consecutive treatments.
Evaluation of the treatment outcome
The 17-item HAM-D was used to evaluate the severity of MDD and was routinely 
performed 1-3 days prior to ECT and 1-3 days after treatment termination to evaluate 
the efficacy of ECT. High inter-rater reliability and internal consistency have been 
shown for this scale (Miller et al., 1985). Since the Montgomery Asberg depression 
rating scale (MADRS) (Montgomery and Asberg, 1979) is more sensitive to detect small 
changes over time (Carmody et al., 2006), the MADRS was performed weekly during 
ECT treatment to evaluate the time to remission. The MADRS was also performed 
1-3 days prior to ECT 1-3 days after ECT. The primary outcome criteria for efficacy are 
mean reduction (continuous) in HAM-D scores per group and proportion of patients 
in remission (dichotomous) as measured by the HAM-D. The secondary outcome 
criterion is time to remission as measured by the MADRS. Remission was defined as 
a HAM-D score of ≤ 7 or a MADRS score of ≤ 9.
Response was defined as a reduction of ≥ 50% on the HAM-D score, relative to the 
baseline HAM-D score.
Statistical analysis
Differences with regards to socio-demographic, clinical, and outcome variables 
between subgroups of patients were tested with T-tests or ANOVA test for continuous 
variables, and Pearson’s Chi-square and Fisher’s Exact test (FET) for categorical 
variables. In case of a 2x3 contingency table, we employed the Freeman-Halton 
extension (Freeman and Halton, 1951) of the Fisher’s Exact test.
Effect sizes were calculated to estimate the magnitude of the effect. Cohen’s d was 
calculated with respect to continuous outcomes (reduction of HAM-D scores) while a 
Relative Risk (RR) was calculated with respect to dichotomized outcomes (proportion 
of patients in remission). A Cohen’s d of 0.2 to 0.3 and a RR of 2 (or 0.50) is seen as a 
small effect; a Cohen’s d around 0.5 and a RR of 3 (or 0.33) as a medium effect; and 
a Cohen’s d of 0.8 and RR of 4 (or 0.25) and higher, as a large effect (Cohen, 1988).
Willemijn Binnenwerk.indd   64 18-3-2020   13:54:36
65
Influence of age, psychotic features and psychomotor retardation on ECT efficacy
To analyze the impact of age and clinical features on time-to-remission, survival 
analyses were conducted using the Kaplan-Meier method (Kaplan and Meier, 1958; 
Kleinbaum and Klein, 2012). Log-rank tests were used to test whether the survival 
curves for the age groups were equivalent. Analyses were conducted using SPSS 
version 21.0. Finally, we estimated the mediating effects of psychomotor agitation, 
retardation and psychotic symptoms in the relationship between age (three age 
groups) and reduction of depressive symptoms. The size and significance of all 
direct and indirect paths between age and symptom reduction were estimated using 
structural equation modelling. Robust weighted least squares estimation was used 
to allow the inclusion of continuous and dichotomous variables into the model (Yuan 




Of the 190 patients receiving ECT treatment between 2006 and 2015, 85 were 
excluded because they fulfilled one or more exclusion criteria, 6 patients dropped out 
because they refused further ECT treatment or patients were transferred to another 
department, and 3 patients dropped out because a reliable HAM-D and MADRS score 
was not obtainable due to severity of the depression with catatonic features and/or 
mutism. Finally, 96 patients (67% female) were included for analysis; mean age was 
63.9 (SD 12.3, range 33-96) years (Figure 1). Of these patients, 57 (59%) suffered from 
depression with psychotic features, 29% had an episode duration >1 year, and the 
mean baseline HAM-D-score was 28.8 (SD 6.4).
Table 1 presents the clinical characteristics for the total patient sample and for the 
three age groups separately: YA: <50 years (n=13), MA: ≥50 and <70 years (n=50), and 
OA: ≥70 years (n=33). In the MA group, 63% had pharmacotherapy failure, significantly 
less than in the YA and OA group; in the OA group, 42% of the patients were previously 
treated with ECT, significantly more than in the YA and MA group; in the YA group, 23% 
of the patients had psychotic features, significantly less than in the OA and MA group; 
and none of the patients in the YA group had psychomotor retardation, while more 
than half of the MA and OA patients showed psychomotor retardation. No differences 
between the age groups were found for sex, episode duration >1 year, the presence 
of psychomotor agitation, number of ECT treatments, and baseline HAM-D score.
The mean reduction in HAM-D score was 21.3 (SD 9.0) points. Response was obtained 
in 82 (85%) patients, and 67 (70%) patients met the criteria for remission. The mean 
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number of ECT sessions was 15.0 (SD 4.8). The average ECT charge was 219.6 mC for 
the YA group, 302.4 mC for the MA group and 386.4 mC for the OA group.
Figure 1. Study flow diagram
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12 (92) 31(63) 29 (88) 72(76) X2(2)=8.75; 
p=0.013
Previous ECT treatment, n (%) 1 (8) 4(8) 14 (42) 19(20) FET X2 =14.67; 
p<0.001
Phenomenology
Psychotic features, n (%) 3 (23) 33(66) 21 (64) 57(59) FET X2 =7.94; 
p=0.020
Psychomotor retardationb, n (%) 0 (0) 25(64) 19 (61) 44(54) FET X2=14.97; 
p<0.001




Mean number of ECTs (SD) 15.9 (4.1) 14.0(4.9) 15.5 (5.0) 14.7(4.8) F(2)=1.42; 
p=0.25
Mean baseline HAMD score (SD) 27.5 (4.8) 29.5(7.0) 28.1 (6.3) 28.8(6.4) F(2)=0.66; 
p=0.52
Notes: a Missing N=1; b Missing N=16 
Effect of age on efficacy of ECT
There was no significant difference in HAM-D reduction between the three age groups. 
However, best treatment effect was observed in the MA group. YA showed worst 
effect. Difference (non-significant) between the MA and YA group was medium sized 
and difference between the OA and YA group was small sized. Further, the proportion 
of patients in remission was larger in the MA and OA group than in the YA group; 
however, this difference was not significant. RRs suggest a small effect between the 
YA and MA group and between the YA and OA group (Table 2).
Effect of age on time to remission
The average time to remission was 9.1 weeks in the YA group, 7.4 weeks in the MA 
group, and 7.8 weeks in the OA group. There was no significant difference in time to 
remission when comparing the three age groups. Pairwise comparisons showed a 
trend to significance in favor of the MA group over the YA group (Table 2).
5
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Effect of symptomatology on efficacy of ECT
The efficacy of ECT, as measured by the mean reduction in HAM-D score, was 
significantly superior in patients with psychotic features compared to patients 
without psychotic features; a large effect size was found. However, there was no 
significant difference in the rate of patients attaining remission between patients 
with or without psychotic features; the RR suggests a small effect.
The mean reduction in HAM-D score was significantly larger in patients with 
psychomotor retardation compared to patients without psychomotor retardation, 
with a medium effect size. There was a trend to a significantly higher rate of patients 
attaining remission among inpatients with psychomotor retardation, compared with 
patients without retardation; the RR suggests a small effect.
Small, non-significant differences were found in mean reduction in HAM-D score and 
remission rate between patients with and without psychomotor agitation (Table 2).
Effect of symptomatology on time to remission
Survival analyses support these findings. That is, remission was achieved 
approximately one week earlier in patients with psychotic features and psychomotor 
retardation, and 3 to 4 days earlier in patients without psychomotor agitation. 
However, none of these effects reached significance (Table 2).
Mediating effects of symptomatology
Table 3 and figure 2 show the results of the path analysis. In line with earlier analysis 
the path analysis reports no significant association between age and reduction of 
depressive symptoms (total effect of age), significant direct relationships between 
psychomotor retardation and psychotic symptoms on symptom reduction, and no 
significant relationship between psychomotor agitation and symptom reduction. 
Regarding the indirect paths, we found a significant mediating pathway through 
psychomotor retardation. Psychotic symptoms showed a trend towards mediation. 
Both indirect paths were positive, meaning that older age was associated with more 
psychotic symptoms and psychomotor retardation, resulting in larger depressive 
symptom reduction. With regards to psychomotor agitation, we found a negative non-
significant association. Overall, we found a trend (p=.058) towards mediation of the 
association between age and symptom reduction by clinical features. The direction of 
the remaining direct path between age and symptom reduction conversed to negative 
(older age relates to less symptom reduction), but was not significant.
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<50 yrs (YA) 13 18.3 (9.5) YA vs MA: 
d=0.44
8 (62) YA vs MA: 
RR=0.92




50 22.3 (8.8) YA vs OA: 
d=0.30
35 (70) YA vs OA: 
RR=0.86
7.4 (0.5) YA vs OA: 
X2(1)=1.87; p=0.17
>69 yrs (OA) 33 21.1 (9.2) MA vs OA: 
d=0.13
24 (73) MA vs 
OA:RR=0.92








Present 57 24.2 (8.7) d=0.88 41 (72) RR=1.16 7.3 (0.4)







Present 44 24.6 (9.2) d=0.66 33 (75) RR=1.48 7.5 (0.4)







Present 29 23.8 (8.3) d=0.31 18 (62) RR=0.87 8.3 (0.7)
Absent 51 21.0 (9.5) 36 (71) reference 7.8 (0.4)
Notes: a Missing N=16 
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Figure 2. Path model of the relationship between age, clinical features and ECT eff icacy on depressive 
symptoms. Age is modelled as ordinal variable (three age groups YA <50 yrs; MA ≥ 50 and <70 yrs; OA ≥70 
yrs) (N=96). Standardized coeff icients, standard error and p-value are reported. Signifi cant paths (p<.05) 
are depicted as bold lines; non-signifi cant paths are depicted as dashed lines.
Table 3. Path model: Standardized direct and indirect eff ects of age and clinical features on depressive 
symptoms in patients treated with ECT resulting from SEM-analysis (N=96). Signifi cant eff ects are in 
bold script.
Reduction of Depressive Symptoms
Estimated SE p-value
Age (ordinal)
Direct eff ect -.19 .13 .143
Indirect eff ects .25 .13 .058
Age-Agitation-Depressive symptoms -.03 .04 .346
Age-Retardation-Depressive symptoms .16 .08 .049
Age-Psychotic symptoms-Depressive symptoms .13 .07 .071
Total eff ect .06 .10 .580
Psychomotor agitation
Direct eff ect -.19 .14 .156
Psychomotor retardation
Direct eff ect .45 .12 <.001
Psychotic symptoms
Direct eff ect .52 .19 <.001
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DISCUSSION
Effect of age on the efficacy of ECT
We failed to find a significant difference when examining the primary outcome criteria. 
However, medium sized differences in favor of the middle aged (MA) group and small 
sized differences in favor of the old aged (OA) group when compared with the young 
aged (YA) group suggest a correlation between older age and higher ECT efficacy.
The reduction in HAM-D scores was 3-4 points larger in the OA and MA group when 
compared with the YA group, which is a clinically relevant difference. No differences 
were found between the groups for baseline HAM-D scores. No significant difference 
was found according to the secondary outcome criterion. However, the MA and OA 
group achieved remission almost 1,5 to 2 weeks earlier than the YA group.
The differences between the YA group versus the MA and OA group most likely failed to 
reach significance due to the small number of patients in the YA group. Furthermore, 
the high rate (70%) of patients that met the criteria for remission in the total study 
group made it difficult to detect potential differences in efficacy (i.e. ceiling effect).
Effect of symptomatology on the efficacy of ECT
As measured by mean reduction in HAM-D score, the ECT efficacy was significantly 
superior in patients with psychotic features and a large difference in effect was found. 
The fact that no difference was found between patients with versus without psychotic 
features when comparing rates of patients attaining remission, is probably due to the 
fact that the mean HAM-D baseline score of patients with psychotic features was 6 
points higher compared to the non-psychotic patients. Also, the previous mentioned 
high remission rate of the total group made it difficult to detect potential differences.
Patients with psychomotor retardation had higher ECT efficacy with a significant 
difference when measured by mean reduction in HAM-D scores and trend towards 
significance when measured by remission rates.
Comparison with other studies: influence of age on the efficacy of ECT
Two recent meta-analyses (Haq et al., 2015; van Diermen et al., 2018) found a positive 
association between older age and higher ECT efficacy, but this association was 
weak. Also, the results of the present study with a homogeneous patient population 
found a larger symptom reduction in older age, but this was non-significant. The 
present study found that the association between age and ECT efficacy is mediated by 
psychomotor retardation (p=.049) and in lesser extent by psychotic features (p=.071). 
5
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Thus heterogeneous results in previous studies (Birkenhager et al., 2010; Bloch et al., 
2001; Damm et al., 2010; Nordenskjold et al., 2012; O’Connor et al., 2001; Spashett 
et al., 2014; Tew et al., 1999) may be explained by differences in mediatory factors 
between the studies.
Comparison with other studies: influence of symptomatology on the efficacy of 
ECT and mediating effects of symptomatology
The higher efficacy to ECT we found in patients with psychotic features is in agreement 
with others (Birkenhager et al., 2003; Loo et al., 2011; Petrides et al., 2001). Moreover, 
our finding of a higher efficacy of ECT in patients with psychomotor retardation is in 
accordance with Hickie et al. (1996) who found that marked psychomotor disturbance 
and psychotic features were independently associated with a superior response to 
ECT. In that study, the combination of psychotic features and marked psychomotor 
disturbance was associated with the best response to ECT. In depression with 
psychotic features, biological mechanisms such as shortened REM latency and 
dexamethasone non suppression are very often observed (Staner and Mendlewicz, 
1991). Psychomotor disturbance is one of the strongest indicators of melancholic 
depression (Parker and McCraw, 2017) and melancholic features are also associated 
with biological mechanisms like shorter REM latency and dexamethasone non 
suppression (Rush and Weissenburger, 1994).
In the present study, the positive indirect pathway age-psychomotor retardation, 
meaning that older age was associated with more psychomotor retardation is in 
agreement with Brodaty et al. (1997) who found that psychomotor disturbance is 
more common in elderly patients.
Only a few studies investigated possible explanations for the finding that older age 
predicts a higher efficacy of ECT. O’Connor et al. (2001) suggested that the superior 
response to ECT they found in older age may be a function of a higher percentage 
of psychotic features in older age. In our study, we also investigated psychomotor 
disturbance and psychotic features as a possible explanation for the association 
between age and ECT efficacy. The path analysis showed that psychomotor 
retardation and psychotic features mediate the association between age and ECT 
efficacy. Therefore, the association between age and ECT efficacy may not always 
emerge since the presence of psychomotor retardation and psychotic features may 
vary between studies.
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Strengths and limitations
The present study investigated a sample of severely depressed patients with a mean 
baseline HAM-D score of 29, of which 59% had psychotic features. The homogeneity 
of the diagnosis, the severity of the depressive symptoms and the wide age range 
of the population are considered major strengths. Further, the fact that the use 
of benzodiazepines during ECT was not allowed is considered a strength since 
benzodiazepines have a negative effect at least on the efficacy of right unilateral (RUL) 
ECT (Jha and Stein, 1996). This may also apply to bilateral (BT) ECT. Also, diagnosing 
major depression during a drug-free observation period and the prospective design 
are strengths of this study.
The most important limitations are the relatively small sample size and the fact that 
patients are not equally distributed between the three age groups, with only 14% 
of the patients in the young-age group and over 50% of the patients in the middle-
age group. The exclusion of patients that refused further ECT treatment might have 
overestimated the efficacy of ECT. Our findings pertain to patients treated with BT 
ECT at 1ms pulse width given twice weekly. The findings may not be generalizable to 
RUL, BF (bifrontal) or BT ECT at different frequency.
Psychomotor retardation and agitation were defined according to item 8 and 9 of the 
HAM-D17, respectively, which is another limitation. In analyzing reduction in total 
HAM-D scores it is possible that these specific HAM-D items were partly accountable 
for higher baseline scores since a higher score on item 8 and/or 9 leads to a higher 
total baseline HAM-D score.
Future studies could investigate mediating factors with more precise evaluation tools, 
like the CORE for psychomotor disturbance, and the Psychotic Depression Assessment 
Scale (PDAS) (Ostergaard et al., 2014) for psychotic features, since these tools might 
provide more convincing evidence.
CONCLUSION
ECT is most effective in patients with psychotic features and patients with 
psychomotor retardation showed. Furthermore, our results show that these 
symptoms also mediate the association between older age and ECT efficacy, thereby 
providing a rationale for the heterogeneous results found in scientific studies for the 
impact of age on ECT efficacy. The observation of obvious psychomotor retardation 
may be an argument for treatment with ECT earlier in the treatment algorithm in 
severely depressed patients.
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This report describes a 55-year-old woman who had 1 previous episode of major 
depression that responded favorably to treatment with tricyclic antidepressants. 
After the development of Addison disease, she experienced a new episode of major 
depression that failed to respond to adequate treatment with imipramine and was 
subsequently successfully treated with electroconvulsive therapy (ECT) with steroid 
cover. The patient did not experience adrenal crisis or adverse effects. After 9 ECT 
sessions, she attained full remission. These findings support the suggestion that ECT 
treatment is safe in patients with Addison disease when using 100 mg intravenous 
hydrocortisone as prophylaxis.
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INTRODUCTION
Addison disease, or primary adrenocortical insufficiency, is a rare disorder with 
a mean incidence of approximately 6 new cases per million per year (1). Major 
depression is a frequent occurrence in patients with Addison disease (1). Although 
glucocorticoid replacement may alleviate major depression in these patients, some 
have persistent major depression despite adequate replacement therapy (2).
Major depression is associated with both hypercortisolemia and hypocortisolemia, 
with hypocortisolemia being more prevalent in patients with chronic major 
depression.
Whether the efficacy of antidepressants in patients with depression with Addison 
disease is similar to that in physically healthy patients with depression is unknown.
The patient we describe had 1 previous episode of major depression, which responded 
favorably to treatment with tricyclic antidepressants (TCAs). After the development of 
Addison disease, she experienced a new episode of severe major depression, which 
failed to respond to adequate treatment with imipramine and was subsequently 
successfully treated with electroconvulsive therapy (ECT).
CASE REPORT
This patient is a 55-year-old woman who developed a first major depressive episode 
at age 44 years. The first depressive episode responded favorably to treatment with 
clomipramine 150 mg/d. No recurrence of depression occurred for the next 11 years. 
At the age of 55 years, the patient developed Addison disease. At the same time, she 
developed depressive symptoms that only marginally responded to hydrocortisone 
treatment (30 mg). After decreasing the dose of hydrocortisone to 20 mg because 
of adverse side effects (tremors), the depressive symptoms increased. A depressive 
disorder was diagnosed, and the patient was treated at a psychiatric outpatient clinic. 
Subsequent treatment with clomipramine 150 mg, venlafaxine 225 mg, mirtazapine 
30 mg, and amitriptyline 200 mg had no effect on the severity of her depressive 
symptoms.
About 2 years after the recurrence of major depression, the patient was admitted to 
the depression unit of the Department of Psychiatry at the Erasmus Medical Center 
for diagnostic evaluation and treatment. On psychiatric examination, she exhibited 
bradyphrenia, self-depreciation, depressed mood, psychomotor agitation, and 
suicidal thoughts. The diagnosis of severe major depression was confirmed. Her score 
6
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on the 17-item Hamilton Rating Scale for Depression (HAM-D) was 25. Treatment with 
imipramine was started and, with a daily dose of 150 mg, she attained a therapeutic 
plasma level (262 ng/mL). After 4 weeks of adequate treatment, there was a slight 
worsening of the depressive symptoms (HAM-D score, 31). The patient agreed to a 
trial of inpatient ECT. The imipramine was stopped before the start of ECT treatment. 
Bilateral ECT was performed twice a week with the Thymatron System IV. Anesthesia 
was achieved with intravenous etomidate (0.2 mg/kg) and succinylcholine (1.0 mg/
kg) for muscle relaxation. On the advice of an endocrinologist, hydrocortisone 100 mg 
was administered intravenously as prophylaxis against adrenal crisis (steroid cover) 
just before each ECT session. The patient had no adverse effects, with the exception 
of retrograde amnesia and transient headache after the ECT sessions. After 9 ECT 
sessions, our patient attained full remission (HAM-D score, 5).
DISCUSSION
This woman had experienced several previous episodes of major depression that 
responded favorably to treatment with a TCA. After developing Addison disease, she 
developed a new episode of severe major depression; however, this time she did 
not respond to treatment with imipramine with therapeutic plasma concentrations 
but did respond favorably to ECT, attaining complete remission after 9 ECT sessions.
There are several possible pathways to an increased risk of depressive disorders 
in patients with Addison disease. Psychological and mood impairment has been 
documented in patients with primary adrenocortical insufficiency. This could result 
in an increased risk of depressive disorders. Another explanation is that patients 
with Addison disease have continuous dysregulation of the hypothalamic-pituitary-
adrenal axis that might not be reversed by glucocorticoid hormone substitution (1). 
Glucocorticoid replacement therapy may improve depressive symptoms in Addison 
disease, but some patients have persistent depressive symptoms despite adequate 
replacement therapy (2). In addition, it is not always possible to give an optimal dose 
of hydrocortisone, for instance, because of adverse effects, as was the case in our 
patient.
It remains unclear why our patient no longer responded to TCAs after being diagnosed 
as having Addison disease but achieved full recovery from the depressive disorder 
with ECT. It is possible that the index episode in our patient was more severe than her 
previous episode because of the comorbid Addison disease. In addition, it is likely that 
a more severe depressive episode would not respond to TCAs whereas it would to ECT 
because ECT is a more effective antidepressant treatment compared with TCAs. Yuuki 
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et al showed that patients with a depressive disorder who did not respond to trials 
of antidepressant medication showed remission with ECT that was accompanied by 
resolution of the hypothalamic-pituitary-adrenal dysregulation (3). Vukadin et al (4) 
showed that high levels of postdexamethasone cortisol are associated with a more 
robust response to ECT.
Administration of ECT for major depression in patients with Addison disease has been 
reported in 2 other cases. (2,5). Suzuki et al (2) reported that a patient was treated 
with 13 ECT sessions and 100 mg hydrocortisone intravenously as prophylaxis against 
adrenal crisis. The depressive episode went into remission without adrenal crisis or 
severe adverse effects. Craddock and Zeller (5) treated their patient with a depressive 
disorder and Addison disease with 4 sessions of ECT without steroid cover; this patient 
also responded well to ECT and without adrenal crisis.
Our patient was treated with 9 bilateral ECT sessions with 100 mg hydrocortisone 
intravenously as prophylaxis against adrenal crisis as steroid cover without any severe 
adverse effects or adrenal crisis. Adrenal crisis in patients with Addison disease is a 
life-threatening event that might occur because of the physiologic stress that occurs 
during ECT. That is why we suggest to use steroid cover despite the fact that 1 patient 
with Addison disease was reported to be safely treated with ECT without steroid 
cover (5). The findings from our case report and those of Suzuki et al (2) suggest 
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MAIN CONCLUSIONS OF THIS THESIS
- The efficacy of ECT in MDD is significantly superior in patients without previous 
pharmacotherapy failure as compared with medication resistant patients 
(chapter 3).
- Since the overall remission rate for patients with previous pharmacotherapy 
failure is almost 50% (chapter 3) and 39% of the patients with resistance to a 
strong antidepressant trial (TCA and lithium addition) attain remission after ECT 
treatment (chapter 2), severely depressed medication resistant patients can still 
largely benefit from subsequent ECT.
- ECT appears to be equally effective for bipolar depression as compared with 
unipolar depression (chapter 4). This is important, since bipolar depression is 
hard to treat due to the doubtful effects of antidepressant add-on therapy and 
the additional risk of manic switches.
- Patients with MDD aged 50 or older had non-significant higher efficacy of ECT 
(small to medium effect sizes) compared to patients <50 years (chapter 5).
- Older age was associated with more psychotic symptoms and more psychomotor 
retardation in MDD (chapter 5).
- A superior efficacy of ECT is found in patients with psychotic features and in 
patients with psychomotor retardation and these symptoms mediate the 
association between age and ECT efficacy (chapter 5). This finding provides a 
rationale for the heterogeneous results found in scientific studies for the impact 
of age on ECT efficacy in MDD.
- It is suggested that ECT treatment is safe in Addison disease with 100mg 
intravenous hydrocortisone as prophylaxis (chapter 6).
- No evidence was found for an association between cortisol values after successful 
bilateral ECT and early relapse (chapter 7). This is in line with the majority of ECT 
studies on the relation between persistent HPA axis hyperactivity and relapse 
after successful ECT.
- A strong association between HPA axis hyperactivity after successful treatment 
with antidepressants and relapse that was found in studies, whereas this relation 
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was not found in studies focusing on ECT treated patients exclusively. This 
suggests that ECT treatment affects the HPA axis in a fundamentally different 
way (chapter 7).
METHODOLOGICAL CONSIDERATIONS
The results of the studies should be interpreted in the lights of its strengths and its 
limitations.
Validity and homogeneity of psychiatric diagnosis
The accuracy of the diagnosis in the three prospective studies (chapter 2,5,7) due 
to diagnosing MDD based on clinical observation during a routinely used drug-
free period is considered a strength. Further, the study samples are homogeneous 
samples of severely depressed patients with a mean HAM-D (17 item) baseline score 
between 26.0 and 28.8.
Electroconvulsive therapy
In the prospective studies (chapter 2,5,7), predominantly bilateral ECT was given, 
which is considered to be the most effective electrode placement (1) .
Further, the use of benzodiazepines was not allowed which is considered a strength 
since benzodiazepines have a negative effect at least on the efficacy of right unilateral 
(RUL) ECT (2). This may also apply to bilateral ECT.
Since most patients were treated with bilateral ECT at 1 ms pulse width given twice 
weekly, the findings may not be generalizable to RUL, bifrontal ECT or bilateral ECT 
given a different frequency.
Study design
All three prospective studies (chapter 2,5,7) had relatively small sample sizes, which 
could have influenced the results.
In the study investigating the influence of age the mediation role and psychomotor 
disturbance and psychotic features on ECT efficacy (chapter 5) patients were not 
equally distributed among the three age groups, with only 14% of the patients in the 
YA group and >50% in the MA group. The differences between the YA group versus the 
MA and OA group most likely failed to reach statistical significance due to the small 
number of patients in the YA group.
8
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Further, in this study, psychomotor retardation and agitation were defined according 
to item 8 and 9 of the HAM-D17, respectively. In analyzing reduction in total HAM-D 
scores it is possible that these specific HAM-D items were partly accountable for 
higher baseline scores, since a higher score on item 8 and/or 9 leads to a higher total 
baseline HAM-D score.
In the study testing the hypothesis that persistent HPA axis hyperactivity after ECT 
in MDD predicts early relapse (chapter 7), only 17 patients were included for the 
analysis, which meant we could not adjust for potential confounding factors such 
as medication resistance, episode duration and residual symptoms. In this study 
we found that the majority of patients (75%) with response but without complete 
remission (partial remission; residual symptoms) relapsed compared to only 15% of 
the patients that achieved complete remission. Therefore, it is possible that partial 
remission is a confounding factor. This finding suggests the importance of continuing 
ECT treatment until full remission is achieved.
Measuring cortisol
It is possible that an influence of persistent HPA axis hyperactivity after ECT treatment 
on early relapse has been limited due to the high percentage of our patients with 
hypercortisolemia and non-suppression on the DST after ECT treatment (chapter 
7). Ideally, to measure the cortisol ratio, cortisol is measured at the same time 
before and after dexamethasone ingestion. In this study cortisol was measured at 
11 AM pre dexamethasone and at 9 AM after dexamethasone ingestion the evening 
before. Therefore, there could have been an overestimation of the percentage of 
non-suppressors in this study.
Furthermore, measuring cortisol in saliva in a severely depressed population is prone 
to lead to missing data. It proves to be difficult to fully instruct patients to chew on 
the salivettes for a sufficient amount of time.
Defining medication resistance
When comparing the efficacy of ECT in medication resistant patients versus patients 
without medication resistance, medication resistance (chapter 2 and 3) was defined 
according to the antidepressant treatment history form. This is a physician rated 
instrument to assess treatment resistance. The cutoff point for treatment resistance 
is a score of 3 or more. This score is already attained when treated with an adequate 
dosage of a single selective serotonin reuptake inhibitor for 4 weeks, which generally 
is not considered a strong antidepressant trial.
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Limitations of the meta-analyses
The findings of the meta-analyses (chapter 3 and 4) are based on observational 
studies, since a randomized controlled trial is not feasible in the situation of 
medication resistance and bipolar versus unipolar depression. This may result in an 
increased risk for some form of bias (selection bias for example) and differences in 
study design.
In both meta-analyses (chapter 3 and 4), in several of the included studies patients 
were treated with right unilateral ECT with an electrical stimulus of less than 6x the 
seizure threshold, which is considered less effective than bilateral ECT (1). Therefore, 
ECT administration was less optimal in these studies compared to the remaining 
studies. Further, in some studies, patients were allowed to use lorazepam during 
the ECT course, which can also have a negative effect at least on the efficacy of right 
unilateral (RUL) ECT.
ECT efficacy seems to be superior in depressed patients with psychotic features 
compared to depressed patients without psychotic features (3, 4). In the meta-
analysis comparing the efficacy of ECT in medication resistant patients versus 
patients without medication resistance (chapter 3), the proportion of patients with 
psychotic depression was unequally divided between the studies: two of the included 
studies excluded psychotic depression (5, 6), in two studies a minority of the patients 
had psychotic depression and in the remaining 3 studies almost 50% of patients had 
a psychotic depression. Therefore, it is possible that the proportion of patients with 
psychotic features was a potential confounding factor.
COMPARISON WITH PREVIOUS AND RECENT LITERATURE
Medication resistance and response to subsequent electroconvulsive therapy in 
major depression
We found the efficacy of ECT to be significant superior in patients without 
previous pharmacotherapy failure as compared with medication resistant patients 
with a remission rate of 48% and 65% for patients with and without previous 
pharmacotherapy failure. This is in line with a more recent meta-analysis published 
in 2015 that found response rates of 58% and 70% for patients with and without 
medication failure respectively (p<0.001)(7).
8
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Efficacy of electroconvulsive therapy in bipolar versus unipolar major 
depression
Our finding that ECT appears to be equally effective for both bipolar and unipolar 
depression in terms of remission rates (53% versus 51% respectively) is in line with 
a more recent meta-analysis that found remission rates of 52% in both unipolar 
and bipolar depression (8). On the other hand they found a significant but small 
difference in terms of response rates between bipolar and unipolar depression: 77% 
in bipolar depression compared 74% to unipolar depression. In our study we only 
used the remission criterion since most patients with severe depression will show 
some response to ECT and therefore the response criterion may lack the sensitivity 
needed to detect differences in the treatment efficacy between unipolar and bipolar 
depression.
Influence of age on ECT efficacy in depression and the mediating role of 
psychomotor retardation
The findings of our study are in line of two recent meta-analyses (7, 9) that found a 
positive but weak association between older age and higher ECT efficacy. However, 
heterogeneous results are found in previous studies (10-16).
The higher efficacy to ECT we found in patients with psychotic features is in agreement 
with others (3, 4, 17).
Moreover, our finding of a higher efficacy of ECT in patients with psychomotor 
retardation is in accordance with Hickie et al. (1996)(18).
A large study published in 2018 found no difference in response or remission rate after 
ECT treatment between three age groups (18-45, 46-64, and 65-85 years)(19). The 
majority of patients suffered from a bipolar depression (89%), in contrast to our study, 
in which we excluded bipolar depressions. In this study, there were no significant 
differences in percentage of psychotic features between the 3 age groups in contrast 
to our study, in which the young age group (< 50 years) had significantly less psychotic 
features compared to the middle age (50-69) and old age (70 and over) group. Further, 
in this study (19) the percentage of patients with psychotic features in the middle (46-
64) and older (65-85) age group was lower (28% and 35% respectively) compared to 
the percentage of patients with psychotic features in middle (50-69) and older (70 and 
older) age group (66% and 64% respectively) in our study. Since we found that the 
association between age and ECT efficacy is mediated by psychomotor retardation 
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and in lesser extend by psychotic symptoms it is possible that the association between 
age and ECT efficacy therefore did not emerge in the study of Socci (2018)(19).
Cortisol levels after successful electroconvulsive therapy as a predictor for early 
relapse in major depression
The finding of our study together with the inconclusive results from studies focusing 
on ECT treatment exclusively, are in contrast with the strong association that was 
found between post treatment non-suppression on the DST after clinical treatment 
response and poor long-term outcome in patients treated with antidepressants in 
the meta-analysis of Ribeiro et al. (1993)(20).
The difference between the results in patients treated with antidepressants and 
patients treated with ECT exclusively might be explained by the fact that ECT has a 
different effect on the HPA axis compared with treatment with antidepressants (21). 
This is in line with our case report (chapter 6). Also, ECT treatment itself might affect 
the HPA axis (22, 23). Therefore, the usefulness of cortisol in its present form as a 
biomarker for relapse after successful ECT needs further study.
GENERAL CLINICAL RECOMMENDATIONS
- Diagnose MDD, at least in inpatients, based on clinical observation during a 
routinely used drug-free period to increase accuracy of diagnoses
- Optimize ECT treatment in MDD: consider bilateral ECT (or RUL with an electrical 
stimulus of at least 6x the seizure threshold), refrain from benzodiazepines, 
proceed with ECT treatment as long as the patient improves
- ECT treatment should be continued in severe depression until full remission is 
achieved considering the higher relapse rate in partial remission
- Consider ECT treatment in severe bipolar depression earlier in the treatment 
algorithm, especially since this type of depression often proves to be relatively 
medication resistant and ECT appears to be equally effective for bipolar 
depression as compared with unipolar depression
- When considering ECT treatment, clinicians should focus on the presence of 
psychomotor retardation and psychotic features in MDD instead of focusing on 
the age of a patient
8
Willemijn Binnenwerk.indd   107 18-3-2020   13:54:39
108
Chapter 8
- The observation of obvious psychomotor retardation may be an argument for 
treatment with ECT earlier in the treatment algorithm in severely depressed 
patients
RECOMMENDATIONS FOR FURTHER RESEARCH
Predictors of ECT efficacy in major depression
Although ECT is a very effective treatment in MDD, up to 45% of the patients do not 
achieve full remission. Therefore, it is important to evaluate possible predictors and 
to investigate new predictors of ECT efficacy. Convincing predictors of ECT efficacy 
are absence of medication resistance, psychotic features, previous ECT treatment 
and shorter duration of the index episode.
In this thesis, we found evidence that psychomotor retardation and psychotic features 
predict ECT efficacy. However, we defined psychomotor retardation according to 
item 8 of the HAM-D17. Replication of this finding is warranted in larger studies with 
a more precise evaluation tool, like the CORE or the actiwatch since these tools might 
provide more convincing evidence.
Latency between sleep onset and first episode of rapid eye movement (REM) sleep 
is typically shortened in MDD and small studies show that ECT improves sleep 
parameters, increased REM sleep latency and decreased duration of REM sleep (24). 
Therefore, it may be of interest to investigate the relation between sleep and ECT 
using polysomnography to understand the mechanisms of ECT better and to assess 
whether sleep parameters may be interesting candidates as predictor of ECT efficacy. 
However, the achievability of polysomnography is questionable, since it might be a 
difficult procedure to fulfill in severely depressed patients.
Cortisol is another challenging predictor of ECT efficacy to investigate, since ECT 
treatment itself may affect the HPA axis too. Therefore, it is important first to 
investigate which effect ECT itself has on the HPA axis.
On the other hand, specific predictors are maybe less useful to personalize treatment 
strategies. Further research should focus on identifying how known clinical and 
biological predictors complement and interact with each other in order to build a 
more complex multidimensional prediction model, which may predict ECT efficacy 
far more accurately than the individual predictors.
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Predictors of relapse after successful ECT in major depression
Further investigation of other possible predictors of relapse after successful ECT 
treatment in MDD is justified because of the substantial relapse rate. We did not find 
an association between persistent HPA axis hyperactivity after successful ECT and 
relapse (chapter 6). This in agreement with the majority of previous studies focusing 
on relapse after ECT treatment exclusively. Further, ECT itself may increase cortisol 
levels and there are signs that ECT treatment affects the HPA axis fundamentally 
different than antidepressant treatment does. Therefore, the usefulness of cortisol 
assessment in its present form to predict relapse after successful ECT is questionable 
and it needs further study. It may be useful to assess cortisol before, during and 
after ECT in order to understand the effect of ECT treatment on the HPA axis better. 
Further, we suggest assessing cortisol during the follow-up period after successful 
ECT since ECT treatment itself may affect the HPA axis, which may offset the expected 
normalization of the HPA axis.
It could also be worth investigating which treatment options, for example the 
combination of antidepressant therapy and a psychological treatment form like 
cognitive behavioral therapy, reduce the risk of relapse. Only one randomized 
controlled trial investigated CBT combined with antidepressants as maintenance 
therapy after successful ECT in depressed patients and found that this combination 
might be an effective continuation treatment to prevent relapse after successful ECT 
(25). Replication of this study is of value and assessing other forms of psychotherapy 
as relapse prevention after successful ECT could be of interest.
8
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Severe major depression (MDD) is a serious, sometimes life-threatening illness. 
Therefore, effective treatment is essential. ECT is a highly effective treatment in MDD. 
Nevertheless, up to 30-45% of the patients do not achieve full remission (1), and high 
relapse rates after successful ECT treatment remains a major cause for concern (2).
Reliable predictors of ECT efficacy and relapse after successful ECT treatment would 
be useful to guide patient treatment matching.
Therefore, we examined possible predictors of ECT efficacy and possible predictors 
of early relapse after successful ECT in MDD.
In chapter 2 we present an open prospective study investigating the predictive 
value of treatment failure to both a TCA and lithium addition with respect to the 
efficacy of subsequent ECT. This study included 86 patients with a mean post-ECT 
HAMD score of 10.7. Patients with nonresponse to a TCA and lithium addition had a 
mean decrease in HAM-D score during the ECT course of 16.4 compared to 19.5 in the 
patient group without medication resistance (p=0.2) (primary outcome criterion). 
Furthermore, response rates were 67% in the group adequately treated versus 77% in 
the inadequately treated group (p=0.3). Remission rates were 39% in the medication 
resistant group versus 50% in the group without medication resistance (p=0.3). 
Therefore, treatment failure with adequate pharmacotherapy with an TCA and lithium 
addition appears to be unrelated to outcome following subsequent ECT.
Since failure to respond to antidepressants is the most common indication for ECT 
and the literature seems to be divided as to whether medication resistance has a 
negative influence on the efficacy of subsequent ECT, we performed a meta-analysis 
(chapter 3) to investigate the effect of previous pharmacotherapy failure on the 
efficacy of subsequent ECT. We conducted a systematic literature search and included 
7 prospective, observational studies in the meta-analysis. We observed the overall 
remission rate of patients without previous pharmacotherapy failure (64.9%) to be 
significantly superior to the remission rate of patients with previous pharmacotherapy 
failure (48%) (OR=0.52, 95% CI: 0.39-0.69). Therefore, this meta-analysis provides 
evidence that the efficacy of ECT appears to be superior in patients without 
medication resistance compared with medication-resistant patients. Despite the 
significant difference between patients with and without previous pharmacotherapy 
failure, almost 50% of medication resistant patients attain full remission with ECT 




treatment. Hence, ECT seems to be an effective treatment for severely depressed 
patients as well as for depressed patients with previous pharmacotherapy failure.
Since possible differences in the efficacy of ECT for unipolar versus bipolar depression 
remain unclear, we performed a meta-analysis (chapter 4) to investigate the efficacy 
of ECT in bipolar versus unipolar major depression. We conducted a systematic 
literature search and included six cohort studies (5 prospective and 1 chart review) 
in the meta-analysis. The overall remission rate for patients with unipolar depression 
was similar (50.9%) to patients with bipolar depression (53.2%) (OR=1.08, 95% CI: 
0.75-1.57). Accordingly, this meta-analysis provides evidence for the equal efficacy 
of ECT in both types of MDD. No hint for a difference in efficacy of ECT in both types 
of MDD emerged.
Since it is uncertain whether patients’ age influences ECT efficacy in MDD, we 
tested the hypothesis that older age predicts a higher efficacy of ECT and a shorter 
time to remission in severely depressed patients (chapter 5). Furthermore, we 
analyzed whether psychomotor disturbance and/or psychotic features mediate the 
relationship between age and ECT efficacy. Ninety-six patients of the PROSPECT 
cohort (a prospective study of depressed patients treated with ECT at the Department 
of Psychiatry of the Erasmus Medical Centre from January 2006 up to date) were 
included for analysis. Middle aged (MA; 50 to 70 years) and older aged (OA; 70 years and 
over) patients had non-significant larger symptom reduction compared with young 
aged (YA; <50 years) patients. Medium effect size was found in favor of MA (d=0.44) 
compared to YA and small effect size was found in favor of OA (d=0.30) compared 
to YA. The MA and OA group achieved remission almost 1,5 to 2 weeks earlier than 
the YA group; a difference that did not attain the level of statistical significance. 
Patients with psychotic features and patients with psychomotor retardation had 
significantly larger symptom reduction (p<0.001 and p=0.005, respectively, d=0.88 
and d=0.66, respectively) than patients without these features. In the path-analysis 
that we performed we found a significant mediating pathway through psychomotor 
retardation (p=0.049) and psychotic symptoms showed a trend toward mediation 
(p=0.071). Both indirect paths were positive, meaning that older age was associated 
with more psychomotor retardation and psychotic symptoms resulting in larger 
depressive symptom reduction.
Chapter 6 is a case report that describes a 55 year old woman who had 1 previous 
episode of MDD that responded to treatment with a TCA. After the development 
of Addison disease, (primary adrenocortical insufficiently) a new episode of MDD 
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occurred. She experienced self-depreciation, depressed mood, bradyphrenia, 
psychomotor agitation and suicidal thoughts and her score on the HAM-D was 
25. This episode failed to respond to a TCA (imipramine with therapeutic plasma 
concentrations) but with 9 sessions of bilateral ECT with steroid cover the patient 
experienced complete remission. The patient did not experience adrenal crisis or 
adverse effects. These findings support the suggestion that ECT treatment is safe 
in Addison disease when using 100mg intravenous hydrocortisone as prophylaxes.
Patients with Addison disease have an increased risk of MDD, possibly because these 
patients have a continuous dysregulation of the HPA axis that might not be reversed 
by glucocorticoid hormone substitution. It remains unclear why this patient with 
Addison disease no longer responded to a TCA but experienced full remission with 
ECT treatment. It is possible that this episode was more severe than her previous 
episode, possibly because of the Addison disease. ECT treatment is a more effective 
antidepressant treatment compared with a TCA. It is also possible that ECT has a 
different effect on the HPA axis compared with treatment with antidepressants.
Relapse after successful ECT occurs frequently in depression and therefore it is 
important to investigate potential predictors of relapse. The aim of chapter 7 was 
to test the hypothesis that persistent HPA axis hyperactivity predicts relapse after a 
successful course of bilateral ECT. In total, 17 patients responded to ECT and were 
included in the study. In these patients salivary cortisol was collected at 10pm 
after successful ECT, which provides information about the basal activity. Further, 
information about the negative feedback system was provided by the dexamethasone 
(0.5mg) suppression test: salivary cortisol levels at 11 AM after successful ECT were 
divided by cortisol levels 10 hours after ingestion of dexamethasone 0.5mg (cortisol 
suppression ratio) the day after. The relation between these cortisol values and 
relapse 3 months after successful ECT was evaluated.
The mean cortisol level at 10 PM was 8.8 nmol/l (SD 5.2) after successful ECT, with 
75% of the total patient population suffering from hypercortisolism (using an 
established reference range of < 6nmol/l (3)). Although not statically significant, more 
hypercortisolism was seen in patients without relapse at 3 months follow-up, i.e. 
86% of patients without relapse (6/7) compared to 60% of patients with a relapse 
(3/5) =0.25, 95%CI:0.02-4.00, p=0.13), which was the opposite direction of which was 
hypothesized. Further, non-suppression on the DST, defined as a cortisol suppression 
ratio of <1.58 (in accordance with Vreeburg et al., 2009(4)) was found in >80% of the 




included patients. Non-suppression rates differed not significantly between patients 
with or without relapse (OR=0.50, 95%CI 0.02-11.09, p=0.21).
Based on these findings, we could not confirm the hypothesis that persistent 
hyperactivity of the HPA axis after successful bilateral ECT is a predictor for early 
relapse. Therefore, no indication was found to continue ECT treatment until 
normalization of the HPA axis was achieved in order to minimize relapse risk.
REFERENCES
1. Kellner CH, Tobias KG, Wiegand J. Electrode placement in electroconvulsive therapy (ECT): 
A review of the literature. J ECT. 2010; 26(3): 175-80.
2. Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain MM, Rasmussen K, et al. 
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in 
major depression: a multisite study from the Consortium for Research in Electroconvulsive 
Therapy (CORE). Arch Gen Psychiatry. 2006; 63(12): 1337-44.
3. Aardal E, Holm AC. Cortisol in saliva--reference ranges and relation to cortisol in serum. 
Eur J Clin Chem Clin Biochem. 1995; 33(12): 927-32.
4. Vreeburg SA, Kruijtzer BP, van Pelt J, van Dyck R, DeRijk RH, Hoogendijk WJ, et al. 
Associations between sociodemographic, sampling and health factors and various salivary 
cortisol indicators in a large sample without psychopathology. Psychoneuroendocrinology. 
2009; 34(8): 1109-20.




Een depressie is een ernstige en soms zelfs levensbedreigende ziekte. Daarom 
is een effectieve behandeling essentieel. Electroconvulsietherapie (ECT) is een 
zeer effectieve behandeling bij patiënten met een ernstige depressieve stoornis. 
Desalniettemin bereikt 30-45% van de patiënten geen volledige remissie (1), en 
hoge terugval percentages na een succesvolle ECT kuur blijven een reden tot zorg (2). 
Betrouwbare voorspellende factoren voor de effectiviteit van ECT en voorspellers van 
terugval na een succesvolle ECT kuur zijn zinvol om zo de patiënt-treatment matching 
te verbeteren. Om die reden hebben we mogelijke voorspellers van ECT effectiviteit 
en mogelijke voorspellers van vroege terugval na succesvolle ECT bij patiënten met 
ernstige depressie onderzocht en in dit proefschrift besproken.
In hoofdstuk 2 bekeken we in een open, prospectieve studie of medicatieresistentie 
voor een tricyclisch antidepressivum (TCA) met lithiumadditie zorgde voor een lagere 
kans op een succesvolle daarna gegeven ECT kuur. In deze studie werden 86 patiënten 
geïncludeerd. Zij hadden een gemiddelde score op de Hamilton Depressie schaal 
(HAM-D) na de ECT kuur van 10.7. Patiënten die resistent waren voor een TCA met 
lithium additie (adequaat behandeld) voorafgaand aan de ECT kuur hadden een 
gemiddelde daling in HAM-D score (HAM-D score pre ECT minus HAM-D score post 
ECT) van 16.4 in vergelijking met 19.5 in de groep zonder medicatie resistentie (niet 
adequaat behandeld) (p=0.2). Het percentage patiënten met respons was 67 in de 
groep die adequaat behandeld was met een TCA met lithium additie versus 77 in de 
niet adequaat behandelde groep (p=0.3). Het percentage patiënten met remissie 
was 39 in de adequaat behandelde groep versus 50 in de niet adequaat behandelde 
groep (p=0.3).
Medicatieresistentie voor adequate farmacotherapie met een TCA met lithium additie 
lijkt daarom niet gerelateerd aan de effectiviteit van de daarna gegeven ECT kuur.
Tegenwoordig is medicatieresistentie de meest voorkomende indicatie voor 
ECT. Of medicatieresistentie een negatieve invloed heeft op de effectiviteit 
van daaropvolgende ECT, daar blijkt de literatuur verdeeld over te zijn. Om die 
reden voerden we een meta-analyse uit (hoofdstuk 3) om zo het effect van 
medicatieresistentie op de effectiviteit van daarna gegeven ECT te onderzoeken. 
Een systematische zoekopdracht resulteerde uiteindelijk in de inclusie van 7 
prospectieve, observationele studies in de meta-analyse. Het percentage patiënten 
zonder medicatieresistentie die in remissie raakten met ECT (64.9%) is significant 
hoger dan het percentage patiënten met medicatieresistentie die in remissie raakten 




(48%) (OR=0.52, 95% CI: 0.39-0.69). De meta-analyse levert dus bewijs voor hogere 
effectiviteit van ECT bij depressieve patiënten die niet medicatieresistent zijn in 
vergelijking met medicatieresistente patiënten. Ondanks dit significante verschil 
tussen patiënten met en zonder medicatieresistentie bereikt bijna 50% van de 
medicatieresistente patiënten toch nog volledige remissie na de ECT-kuur. ECT blijkt 
dus een effectieve behandeling voor ernstig depressieve patiënten, ook als ze eerder 
niet reageerden op antidepressiva.
In de literatuur bestond onduidelijkheid over een eventueel verschil in effectiviteit 
van ECT tussen ernstige unipolaire en bipolaire depressies. Om die reden voerden we 
een meta-analyse uit (hoofdstuk 4) om de effectiviteit van ECT bij bipolaire versus 
unipolaire depressieve patiënten te onderzoeken. We voerden een systematische 
zoekopdracht uit en includeerden 6 cohort studies (5 prospectieve studies en een 
retrospectief dossieronderzoek) in de meta-analyse. Het remissie percentage van 
patiënten met unipolaire depressie was vergelijkbaar (50.9%) met het remissie 
percentage van patiënten met een bipolaire depressie (53.2%) (OR=1.08, 95% CI: 
0.75-1.57). Uit deze meta-analyse blijkt dus dat ECT even effectief is bij een bipolaire 
als bij een unipolaire depressie.
In hoofdstuk 5 werd de voorspellende waarde van leeftijd geëvalueerd tijdens 
de behandeling met ECT. Tevens werd onderzocht of de veronderstelde hogere 
effectiviteit van ECT bij oudere depressieve patiënten (deels) verklaard werd door 
de aanwezigheid van psychotische kenmerken en/of psychomotore retardatie.
Zesennegentig patiënten van het PROSPECT-cohort (een prospectieve studie van 
depressieve patiënten behandeld met ECT op de psychiatrie afdeling van het Erasmus 
Medisch Centrum van januari 2006 tot heden) werden geïncludeerd voor de analyse. 
Patiënten van middelbare leeftijd (MA; 50 tot 70 jaar) en oudere (OA; 70 jaar en ouder) 
patiënten hadden een niet significant grotere symptoom reductie in vergelijking jonge 
(YA;< 50 jaar) patiënten. Een medium effect grootte werd gevonden ten gunste van MA 
(d=0.44) in vergelijking met YA en een kleine effect grootte werd gevonden ten gunste 
van OA (d=0.30) in vergelijking met YA. De MA en de OA groep bereikten bijna 1,5 tot 
2 weken eerder remissie dan de YA groep; dit verschil was echter niet significant.
Depressieve patiënten met psychotische kenmerken en patiënten met psychomotore 
retardatie hadden significant grotere symptoom reductie (p<0.001 en p=0.005, 
respectievelijk, d=0.88 en d=0.66, respectievelijk) dan patiënten zonder deze 
kenmerken. In de pad-analyse die we uitvoerden, vonden we een significant effect 
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via psychomotore retardatie (p=0.049) en psychotische symptomen lieten een trend 
richting mediatie zien (p=0.07). Beiden indirecte paden waren positief, wat betekent 
dat een hogere leeftijd geassocieerd is met meer psychomotore retardatie en meer 
psychotische symptomen, wat resulteert in een grotere reductie van depressieve 
symptomen na ECT behandeling.
Hoofdstuk 6 is een gevalsbeschrijving waarin een 55-jarige vrouw wordt beschreven 
die een eerdere ernstige depressieve episode doormaakte en destijds succesvol 
behandeld werd met een TCA. Na het ontwikkelen van de ziekte van Addison (primaire 
bijnierschorsinsufficiëntie) ontstond er een nieuwe depressieve episode. Er was 
sprake van een sombere stemming, vertraging van het denken, schuldgevoelens, 
psychomotore agitatie en suïcidale gedachten. De HAM-D score was 25. Er werd 
gestart met een TCA (imipramine onder bloedspiegel controle), echter zonder 
effect. Hierna werd patiënte met ECT behandeld en na 9 sessies bilaterale ECT met 
steroïden dekking was er sprake van volledige remissie. Er was geen sprake van een 
Addison crisis of bijwerkingen tijdens de ECT kuur. Deze bevinding draagt bij aan de 
veronderstelling dat behandeling met ECT veilig is bij patiënten met de ziekte van 
Addison als er gebruikt wordt gemaakt van 100mg hydrocortison intraveneus.
Patiënten met de ziekte van Addison hebben een verhoogd risico op het ontwikkelen 
van een depressieve episode, mogelijk doordat deze patiënten een continue 
disregulatie van de HPA-as hebben die mogelijk niet hersteld kan worden door 
glucocorticoïd hormoon substitutie. Het blijft onduidelijk waarom deze patiënte na 
het ontwikkelen van de ziekte van Addison niet meer reageerde op een TCA, maar 
wel volledige remissie bereikte na een ECT kuur. Het is mogelijk dat deze depressieve 
episode ernstiger was dan haar voorgaande episode, mogelijk ook door de ziekte 
van Addison (die zij tijdens de eerdere episode niet had). ECT is een effectievere 
antidepressieve behandeling in vergelijking met een TCA. Het is ook mogelijk dat 
ECT een ander effect heeft op de HPA-as in vergelijking met de behandeling met 
antidepressiva.
Terugval na succesvolle ECT komt regelmatig voor bij depressieve patiënten. Daarom 
is het belangrijk mogelijke voorspellers voor terugval te onderzoeken. Het doel van 
hoofdstuk 7 was om de hypothese te testen dat persisterende HPA-as hyperactiviteit 
direct na een succesvolle bilaterale ECT kuur terugval binnen 3 maanden voorspelt. In 
deze studie respondeerden in totaal 17 patiënten op ECT en deze werden geïncludeerd 
in de analyse. Van deze patiënten werd na succesvolle ECT speekselcortisol verzameld 
om 22u. Deze waarde geeft informatie over de basale activiteit. Informatie over 




het negatieve feedback systeem werd gegeven door de dexamethason suppressie 
test (DST): speeksel cortisol waarden om 11u na een succesvolle ECT keer werden 
gedeeld door speeksel cortisol waarden 10 uur na inname van dexamethason 0.5mg 
de volgende dag (om 9u) (cortisol suppressie ratio). De relatie tussen deze cortisol 
waarden en terugval 3 maanden na succesvolle ECT werd geëvalueerd.
De gemiddelde cortisol waarde om 22u na succesvolle ECT behandeling was 
8.8nmol/l (SD 5.2), waarbij 75% van de patiënten hypercortisolisme had (er werd 
gebruik gemaakt van een vastgestelde referentie range van < 6nmol/l (3)). Er werd 
meer hypercortisolisme gezien bij patiënten zonder terugval bij 3 maanden (86%) 
in vergelijking met patiënten met terugval (60%), OR= 0.25, 95%CI:0.02-4.00, p=0.13 
(ns), dit was de tegenovergestelde richting van wat we verwachtten.
Non-suppressie op de DST, gedefinieerd als een cortisol suppressie ratio van <1.58 
(in overeenstemming met Vreeburg et al., 2009 (4)) werd gevonden bij >80% van de 
geïncludeerde patiënten. Non-suppressie ratio’s verschilden niet significant tussen 
patiënten met of zonder terugval (OR=0.50, 95%CI 0.02-11.09, p=0.21).
Op basis van deze bevindingen kon de hypothese dat persisterende hyperactiviteit 
van de HPA-as na succesvolle bilaterale ECT een voorspeller is voor vroege terugval 
niet bevestigd worden. Er werd op basis van deze studie geen indicatie gevonden om 
de ECT kuur na klinische verbetering verder te continueren tot normalisatie van de 
HPA-as wordt bereikt om op die manier de kans op een terugval te minimaliseren.
In hoofdstuk 8 worden de belangrijkste conclusies van dit proefschrift beschreven en 
worden de uitkomsten van de studies vergeleken met eerdere en recente literatuur. 
Ook worden de methodologische tekortkomingen en sterke punten van de studies 
besproken. Tenslotte worden algemene klinische aanbevelingen en suggesties 
gedaan voor toekomstig onderzoek.
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